| **Title**       | Bio-collections in autism research |
|----------------|-----------------------------------|
| **Author(s)**  | Reilly, Jamie; Gallagher, Louise; Chen, June L.; Leader, Geraldine; Shen, Sanbing |
| **Publication Date** | 2017-07-10 |
| **Publication Information** | Reilly, Jamie, Gallagher, Louise, Chen, June L., Leader, Geraldine, & Shen, Sanbing. (2017). Bio-collections in autism research. Molecular Autism, 8(1), 34. doi:10.1186/s13229-017-0154-8 |
| **Publisher**  | BMC |
| **Link to publisher's version** | https://doi.org/10.1186/s13229-017-0154-8 |
| **Item record** | http://hdl.handle.net/10379/16479 |
| **DOI**        | http://dx.doi.org/10.1186/s13229-017-0154-8 |
Bio-collections in autism research

Jamie Reilly1*, Louise Gallagher2, June L. Chen3, Geraldine Leader4 and Sanbing Shen1

Abstract

Autism spectrum disorder (ASD) is a group of complex neurodevelopmental disorders with diverse clinical manifestations and symptoms. In the last 10 years, there have been significant advances in understanding the genetic basis for ASD, critically supported through the establishment of ASD bio-collections and application in research. Here, we summarise a selection of major ASD bio-collections and their associated findings. Collectively, these include mapping ASD candidate genes, assessing the nature and frequency of gene mutations and their association with ASD clinical subgroups, insights into related molecular pathways such as the synapses, chromatin remodelling, transcription and ASD-related brain regions. We also briefly review emerging studies on the use of induced pluripotent stem cells (iPSCs) to potentially model ASD in culture. These provide deeper insight into ASD progression during development and could generate human cell models for drug screening. Finally, we provide perspectives concerning the utilities of ASD bio-collections and limitations, and highlight considerations in setting up a new bio-collection for ASD research.

Background

Autism spectrum disorder (ASD) is a group of early onset and heterogeneous neurodevelopmental disorders affecting males (1/42) more often than females (1/189) [1]. The prevalence of ASD has risen rapidly; from 0.5/1000 people in early epidemiological studies of 1960–1970 [2, 3] to 1/68 children of school age according to recent data from the Centre for Disease Control [1].

ASD is characterised by atypical development of social behaviour, communication deficits and the presence of repetitive and stereotyped behaviours [4]. It is highly clinically heterogeneous and accompanied by commonly occurring comorbidities that are not core to the disorder but frequently disabling. Communication deficit also persists in social communication disorder (SCD), and the new diagnosis of SCD (DSM-5) makes it possible to distinguish ASD from SCD individuals. The severity may vary across a range of parameters including ASD symptoms, IQ and comorbid behaviours [4]. For example, 70% ASD patients will have at least 1 comorbid psychiatric disorder [5], such as social anxiety, depression and bipolar disorder [6]. In addition, ASD is frequently associated with epilepsy, gastrointestinal and immune disorders [7].

ASD is a highly heritable complex polygenic condition. Estimated heritability based on family and twin studies are 50–80% [8, 9]. It is strongly linked to genetic factors involving the development and function of the nervous system [10], mitochondrial function [11], the immune system [12] and epigenetic regulations [13]. Genetic risk is attributed to rare copy number variants (CNV) and single nucleotide variants (SNV) acting on the background of common genetic variation (reviewed by [14]). High throughput genome sequencing technologies have facilitated genomic discovery, and advanced bioinformatics methodologies have enabled investigation of protein-protein interactions [15, 16] and functionally related pathways [17, 18]. The pathway to gene discovery has required large-scale international collaborative efforts based on the assembly of large bio-collections that are now publicly available and the subject of this review. In parallel to bio-collections, large-scale patient registries have provided epidemiological data that illustrate the course and prognosis of ASD and are helping to identify environmental factors influencing the aetiology [19–22].

Despite the advances, significant gaps in our knowledge of the aetiology remain and effective treatments for core ASD symptoms are elusive. The genetic and clinical heterogeneity of ASD means that further advancement will require larger bio-collections coupled with rich clinical data, ideally longitudinally to obtain a clear picture of
the disorder both on the molecular and physiological levels.

**Autism bio-collections**

A bio-collection is a large set of biologically characterised samples, such as blood or tissue collected from a group of individuals who typically have a specific medical condition. Bio-collections are useful as a dedicated resource to generate clinical and scientific data for the analysis of medical conditions on a large scale [23], as well as to create functional disease models to explore the biology of clinical conditions. Large-scale bio-collections and associated comprehensive data that can aid the interrogation of the relationship between the genotype and phenotype effects at the individual and group levels can address the issue of heterogeneity. The purpose of this review is to provide a summary of the publicly available ASD bio-collections, to highlight the impact of these on ASD research and to identify new directions for ASD bio-collection for future research purposes.

**Methods and search criteria**

A literature search was conducted amongst published studies from Jan 2001 to Nov 2016 on electronic databases of Web of Science, EBSCO, PubMed, Science Direct, MEDLINE, Wiley Online Library. The search terms included “biobank”, “registry”, “collection”, “autism” and citation of bio-collections. A total of 263 studies from ASD bio-collections have been included in the tables and references of this review (Tables 2, 3, 4, 5 and 6).

**Inclusion criteria**

This review included (a) studies using original samples of human tissues in ASD bio-collections; (b) studies using bio-samples extracted from systematically collected bio-resources (i.e. DNA, RNA, protein) for investigating the risk or influence of ASD; (c) the population studies involving participants of autism, Asperger and pervasive developmental disorder not otherwise specified (PDD-NOS); (d) studies published in peer-reviewed journals and (e) in English.

**Exclusion criteria**

Studies were excluded (a) if they did not mention the collection(s) in the research data, references, acknowledgements or supplementary materials; (b) if the bio-samples were not derived from a systematic sample collection; and (d) if studies only concerned animal models of ASD without using ASD bio-collections or data.

We focus largely on studies from five bio-collections, four providing DNA, cell lines and metabolites, the Autism Genetic Resource Exchange (AGRE), Simons Simplex Collection (SSC), The Danish Newborn Screening Biobank (DNSB) and The Autism Simplex Collection (TASC) one providing brain tissue, Autism BrainNet (formerly the Autism Tissue Program (ATP)). We also included two emerging bio-collections that have fewer or no publications released yet, but could be of significant impact in the future. They are the Autism Inpatient Collection (AIC) [24] and the Autism Spectrum Stem Cell Resource [25]. An overview of the bio-collections and their website links can be found in Table 1.

**Results**

**Autism Genetic Resource Exchange (AGRE)**

AGRE was established in 1997 by the Cure Autism Now (CAN) Foundation and the Human Biological Data Interchange (HBDI). Samples are provided by families with children affected by ASD and are coupled with anonymously coded clinical diagnostic data, such as Autism Diagnostic Interview–Revised (ADI–R) and Autism

| Name | Founded | Location | Type of sample collected and stored | Website/source paper |
|------|---------|----------|------------------------------------|----------------------|
| Autism Genetic Resource Exchange (AGRE) | 1997 | USA | Blood and immortalised cell lines | AGRE, www.agre.org |
| Simons Simplex Collection (SSC) | 2010 | USA | Blood and immortalised cell lines | https://sfari.org/resources/autism-cohorts/simons-simplex-collection |
| Danish Newborn Screening Bio-collection | 1980’s | Denmark | Dried blood spot samples | http://www.ssi.dk/Diagnostik/Center%20for%20Neonatal%20Screening/Den%20Neonatale%20Screenings%20Biobank.aspx |
| Autism Tissue Program | 1998 | USA | Post-mortem brain tissue | [https://autismbrainnet.org/researchers/](https://autismbrainnet.org/researchers/) |
| Autism Spectrum Stem cell Resource | 2014 | USA | Skin fibroblasts, blood, induced pluripotent stem cells, neural stem cells, neuronal cells, glial cells | [25] |
| The Autism Simplex Collection | 2010 | USA and Europe | Blood | [97] |
| Autism Inpatient Collection | 2014 | USA | Blood and lymphoblasts | [24] |
Diagnostic Observational Schedule (ADOS). Additional clinical data include photographic dysmorphology, neurological and physical examination, and family and medical history. AGRE is currently managed by Autism Speaks. It contains over 2500 families and the resource has contributed to high profile genetic discoveries relating to ASD (Table 2). Samples are housed at the National Institute of Mental Health repository at Rutgers’ University in the form of immortalised cell lines, DNA and serum samples which can be accessed by researchers through applications [20].

The AGRE resource has been used extensively in genomics studies in ASD. Approaches have included gene-mapping such as genome-wide linkage and association studies in addition to studies of chromosomal structure, particularly the identification of copy number variants. Important ASD chromosomal regions identified include microdeletions and microduplications of 16p11.2 [26, 27], rearrangements and microdeletion/duplication of 15q13.2q13.3 [28–31], common variants in the 5p14.1 region [32, 33], Neuramins and 11p12–p13 [34].

It has also helped in identification of recurrent candidate genes, such as MECP2 [35–37], PTEN [38, 39], EN2 [40–42], RELN [40, 43–46], RORA [47], MET [48–50], NGLN3-A [51], BZRAP1 [28], SLC6A4 [40, 52] GABA receptors [32, 43, 53–55], CACNA1G [56] and the sodium channel genes SCN1A, SCN2A and SCN3A [57].

These studies particularly highlighted an important role of de novo and large inherited copy number variations (CNVs), which are detected in 10% of sporadic ASD [58], which has been widely replicated in other biocollections [59–71]. The use of AGRE combined with other AGP resources have uncovered SHANK2, SYN-GAP1, DLGAP2 and the X-linked DDX3-PITCHD1 locus as novel ASD genes, as well as pathways of cellular proliferation, signalling, neuronal projection and motility [72]. AGRE samples formed a replication set in a separate analysis highlighting CNVs of neuronal cell adhesion and ubiquitin pathway in ASD [73].

AGRE lymphoblastoid cells enabled studies into shared ubiquitin and neuronal gene expression in lymphoblastoid cells and brain [73, 74], glutathione metabolism, oxidative stress [75, 76] and stress response [77], microRNAs and their use in ASD profiling [78, 79], CYFIP1 dosage effect on mTOR regulation [80], and changes in methylation patterns of RORA and BLC2 and their effects on apoptosis, cellular differentiation, inflammation and neural development [47].

The AGRE collection was also used to establish genetic methodologies and bioinformatic tools. This included using mismatch repair to detect amplicons in ASD [81], using multiplex ligation-dependent probe amplification (MPLA) to improve detection of microduplications and microdeletions [82], and incorporating disease symptoms to improve linkage detection in genetic data [83] and analysis of genetic loci to search for candidate genes [84].

### Simons Simplex Collection (SSC)

The SSC is a genetic and clinical repository, which contains material derived from 2600 families. Whereas the AGRE contains multiplex families and trios, The SSC ascertained “simplex” ASD families defined as families where only one child has ASD and at least one other typically developing sibling. DNA is available for both parents, the affected child and an unaffected sibling. Thus the SSC samples are particularly valuable in evaluating parental inheritance. Samples were collected at multiple sites and were stored as immortalised cell lines at Rutgers University Cell and DNA Repository (RUCDR). Each sample was verified for parentage, gender and Fragile X mutation. In-depth clinical phenotypes were characterised for all participants to support genotype-phenotype analyses. These included data on diagnostic status, medical and psychiatric comorbidity, family history and medication use for the affected person. Broader ASD phenotype measures were collected for unaffected family members.

The SSC has become a vast resource of ASD and contributed significantly to numerous Whole exome sequencing studies of ASD in the past ~7 years (Table 3). The main findings showed that de novo mutations were frequently enriched in ASD patients [60]. Whole-genome sequencing results showed a significant enrichment of de novo and private disruptive mutations in putative regulatory regions of previously identified ASD risk genes. It also identified novel risk factors of CANX, SAE1 and PIK3CA with small CNVs and exonspecific SNPs, which were overlooked in previous CNV studies or exxon sequencing [85]. It has also been observed that many de novo mutations were of paternal origin (4:1) and positively correlated with paternal age, [65]. The disruptive mutations were located in genes involve in transcription regulation, chromatin remodelling and synapse formation [86, 87].

The SSC has enabled detection of the ultra-rare “recurrent” CNVs. This included duplications of 7q11.23, 15q11.2 (NIPA) and 16p13.11, and deletion/duplication of 16p11.2, 16p13.2 (USP7), 1q21.1, 2p16.3, 7q31.1, 15q13.2–q13.3, 16p13.3, 20q13.33 and 22q11.21 [60]. The SSC also helped identify recurrent gene mutations in ASD include CHD8, NTNG1, GRIN2B, SCN1A and LAMC3, which are important for transcriptional regulation, neuronal differentiation and function [87].

CHD8 was further evaluated as an ASD candidate gene in children with developmental delay or ASD, and 15 independent mutations were identified and enriched...
| Reference | Bio-collection | Samples | Number | Study | Findings |
|-----------|----------------|---------|--------|-------|----------|
| [35]      | AGRE Genomic data (AGRE), brain tissue (mouse) | 4327 samples (AGRE) 8789 samples (total) | Genotype-phenotype study | HMGN1 found to be a negative regulator of MECP2 expression. Dysregulation alters behaviour in mice, and AGRE collection contains genotypes linked to altered expression |
| [180]     | AGRE Blood 152 subjects | 152 subjects | Quantitative trait analysis | Chromosome region 7q found to be a risk region for Autism Symptoms |
| [181]     | AGRE Lymphoblasts 1438 subjects | Association study | CNTNAP2 identified as an ASD susceptibility gene |
| [182]     | AGRE Blood 1794 subjects | Linkage analysis | Chromosome 7q35 may harbour a gene that could contribute to variability in spoken language |
| [183]     | AGRE Genomic data 455 subjects | Pedigree study | Association found with chromosome X region Xp22.11-P21.2, where gene IL1RAPL1 is located and also implicated in ASD |
| [184]     | AGRE Blood and lymphoblasts 252 families | Gene expression analysis and association | ROBO1-4 found to be associated with ASD. Low expression levels of ROBO1-2 found in ASD patients |
| [185]     | AGRE Blood and lymphoblasts 3211 subjects | Gene association study | Analysis of SNP polymorphisms in PCDHA suggest it as a potential candidate gene for ASD |
| [186]     | AGRE and ATP Lymphoblasts and brain tissue 3211 subjects (AGRE) 21 subjects (ATP) | Gene association study | ZNF804A found to be associated with ASD and verbal deficits, where knockdown of this gene reduced expression of SNAP25, and both are reduced in the anterior cingulate gyrus in ASD brains |
| [187]     | AGRE Blood and lymphoblasts 72 families | Association study | Common variant found in CNTNAP2 that is linked to ASD susceptibility |
| [43]      | AGRE Blood 470 families (total) 224(AGRE) | Association study | GABRB3 and GABRG3 found to be associated with ASD |
| [188]     | AGRE Blood and lymphoblasts 975 subjects | CNV analysis | Analysis of 15q13.1-3 region revealed APBA2 as an ASD candidate gene |
| [189]     | AGRE Blood and lymphoblasts 1577 subjects (total) 1526 subjects (AGRE) | CNV analysis | CNTNAP2 detected in ASD patients suggested to have a contribution to the disorder |
| [74]      | AGRE Lymphoblasts 6 subjects | Proof of principle | 48 genes showed differential expression between patients and controls. Many genes involved in signalling, focal adhesion and metabolism |
| [190]     | AGRE Lymphoblasts 18 subjects* (controls provided by AGRE) | Profiling study | Altered levels of UBE4A (1.5–2 fold increase) expression found in ASD patients with 15q11-14 duplications. APP and SUMO found to be decreased, and are involved in apoptosis |
| [40]      | AGRE Blood and lymphoblasts 334 families | Reanalysis of data set using different analysis method | Association found in chromosome 1, which was previously overlooked. Further evidence that 17q11 is associated with ASD |
| [191]     | AGRE Genomic data 12 families | Method paper | Description of parent of origin method to detect mosaic chromosomal abnormalities. |
| [192]     | AGRE Blood and lymphoblasts 518 families | Replication study and functional study | The gene EN2 suggested to act as ASD susceptibility locus, and mutations could alter brain development |
| [41]      | AGRE Blood and lymphoblasts 389 families (AGRE) 518 families (total) | Association study | Haplotypes found in ASD families found to affect regulation of EN2 gene expression |
| [75]      | AGRE Blood and lymphoblasts 954 subjects | Gene-gene interaction study | Glutathione pathway is implicated in autism |
| Study ID | Collection | Subjects | Study Type | Method/Findings |
|---------|------------|----------|------------|----------------|
| [28]    | AGRE       | Blood and lymphoblasts | 6056 subjects (TOTAL) 4444 subjects (AGRE) | GWAS | UBE3A, NRXN1, B2RAP, and MDGA2 found to have disruptive CNVs amongst ASD patients, some only occurring once amongst patients |
| [83]    | AGRE       | Genomic data | 830 subjects | Methods paper | Use of disease symptoms improves detection of linkage in genetic data. Useful when heterogeneity is involved |
| [38]    | AGRE       | Blood | 18 subjects | Genotype-phenotype study | 3 out of 18 patients with ASD and macrocephaly had mutations in PTEN gene. Considered as ASD gene to be explored |
| [39]    | AGRE       | Blood and lymphoblasts | 88 subjects (total) 39 subjects (AGRE) | Mutation screening | De novo missense mutation found in one patient with ASD and macrocephaly. |
| [193]   | AGRE       | Blood and lymphoblasts | 95 families | Gene linkage study | Chromosome region 2q suggested to contain an autism susceptibility gene |
| [53]    | AGRE       | Blood | 88 families (total) 62 families (AGRE) | Linkage analysis | GABRB3 polymorphism found to be associated with ASD |
| [194]   | AGRE       | Blood | 115 families | Linkage analysis | Analysis carried out for a ASD family subset with obsessive compulsive behaviours (n = 35) found evidence of linkage to chromosome 1 and further evidence on chromosome 6 and 19 |
| [82]    | AGRE       | Blood and lymphoblasts | 279 subjects | Method paper | Multiplex ligation-dependent probe amplification shown to be effective at detecting microduplications and deletions |
| [50]    | AGRE       | Genomic data | 748 subjects | Association study | MET variants associated with social and communication phenotypes amongst people ASD |
| [49]    | AGRE       | Blood and lymphoblasts | 2712 subjects (total) 631 subjects (AGRE) | Association study | Multiple genes implicated in the MET pathway with ASD, such as PLAUR and SERPIN1 |
| [48]    | AGRE       | Blood | 743 families (total) 283 (AGRE) | Association study | MET promoter variant that decreases expression found to be associated with ASD |
| [195]   | AGRE       | Blood and lymphoblasts | 109 subjects | Replication study | Independent sample from the same cohort showed same linkage association to chromosome region 17q21 |
| [196]   | AGRE       | Blood | 480 families | Genetic score study | 3 risk SNPs (ATP2B2, PITX1, HOX41) had high reproducibility in males, 2 in females (MARK1, ITGB3), and 3 across both genders (CTNAP2, JARID2, EN2). |
| [197]   | AGRE       | Blood | 381 subjects | Association study | Association between ASD in males and ATP2B2 |
| [198]   | AGRE       | Blood | 2569 subjects | Functional genomics study | Combining functional genomics and statistical analysis helped identify common variants in ASD |
| [199]   | AGRE       | Blood | 2837 subjects | Association study | Rare haplotype affecting promoter of DLX1 found to be associated with ASD. No common variants found for DLX genes and GADT1 |
| [200]   | AGRE       | Blood | 2261 subjects | GWAS | The chromosome regions Xp22.33/Yp11.31 suggested to harbour male specific variants for ASD |
| [201]   | AGRE       | Blood | 1132 subjects | QTL analysis | Chromosome regions 16p12.13 and 8q23-24 linked to harbour genes contributing to deficits in non-verbal communication in autistic patients |
| [202]   | AGRE       | Blood | 993 subjects | Association study | Glu27 allele of ADRB2 gene suggested to confer increased risk of autism, with pregnancy related stressors having an increased effect |
Table 2 Overview of studies using the AGRE collection (Continued)

| Ref | Source | Method | Sample Size | Findings |
|-----|--------|--------|-------------|----------|
| [203] | AGRE Blood and brain tissue | 90 subjects | Gene identification | Identification of the gene CORTBP2 from autism candidate region 7q31 |
| [54] | AGRE Blood | 611 families | Association study | Reinforced evidence that GABRA4 and GABRB1 are implicated in ASD. Other ethnic groups found to have SNPs in these genes |
| [204] | AGRE Blood | 228 families (total) 38 (AGRE) | Association study | HOXG1 polymorphism A218G found to be associated in increased head circumference amongst ASD patients |
| [205] | AGRE Genomic data | 2165 subjects + 1165 families (total) 2165 subjects (AGRE) | GWAS | Associations found in the following genes with ASD and linked co-morbidities; KNDZ2, NOS2A and NELL1 |
| [206] | AGRE DNA | 37 twin sets (total) 15 twin sets (AGRE) | Association study | Terbutaline exposure for two or more weeks associated with increased concordance for ASD. 2 polymorphisms for ADRB2 associated with ASD |
| [207] | AGRE Blood | 284 families (total) 38 families (AGRE) | Linkage/association study | Variants of PON1 found to be associated with ASD families in North America, but not in Italian families |
| [208] | AGRE Blood | 38 subjects | CNV study | Microdeletions and duplications on chromosome regions 3p26.3, 6q24, 22q11.2, 4q34.2 and 1q24 linked to ASD with physical anomalies. Genes STXBP5 and LRRTM1 identified as candidate genes |
| [209] | AGRE SSC Genomic data | 2294 subjects (SSC) 579 subjects (AGRE) 35663 | CNV analysis | Exploration of evolution of human specific SRGAP2 genes. Rare duplications observed in SSC cohort for SRGAP2C. |
| [210] | AGRE Genomic data from [211] | 121 families | QTL-analysis | 2 loci were identified in chromosomes 11 and 17 associated with social responsiveness in ASD families |
| [81] | AGRE Blood | 411 families (total) 371 families (AGRE) | Method paper | Detection of amplicons using mismatch repair. More amplicon variants were found in patients compared to controls |
| [212] | AGRE Blood | 66 subjects | Metabolite analysis | ASD families have lower levels of unprocessed Reelin protein in blood than controls |
| [213] | AGRE Blood | 90 subjects | Gene characterisation | CADPS and CADPS2 characterised and cloned. Found to be activators of protein secretion. No disease specific variants found amongst ASD patients |
| [214] | AGRE Genomic data | 1146 subjects | Linkage analysis | Linkage peaks found for language—speech phenotypes consistent with potential motor speed disorder in following chromosome regions; 1q24.2, 3q25.31, 4q22.3, 5p12, 5q33.1, 17p12, 17q11.2, 17q22, 4p15.2 and 21q22.2. Multiple candidate genes were also identified |
| [215] | AGRE Blood | 2140 subjects | Linkage analysis | Parental origin effect significantly linked to chromosomes 4, 15 and 20 |
| [42] | AGRE Blood | 167 families | Association study | EN2 found to be associated with ASD susceptibility |
| [216] | AGRE Blood and lymphoblasts | 537 subjects (total) 34 subjects (AGRE) | CNV analysis | Proposal that increased CNV load, particularly duplication of base pairs, predisposes to ASD. Negative correlation found with CNV load and social and communication skills. Applied to both common and rare CNVs |
| Study ID | Collection | Sample Description | Sample Size | Method | Findings |
|---------|------------|-------------------|-------------|--------|----------|
| [73]    | AGRE       | Blood and lymphoblasts | 4714 subjects (total) 1336 subjects (AGRE) | CNV analysis | Genes involved in Neuronal adhesion (NLGN1, ASTN2) and ubiquitin pathways (UBE3, PARK2, RFWD2, FBXD43) were found in ASD patients. Further evidence of NRXN1 and CNTN4 involved with ASD. |
| [217]   | AGRE       | Blood             | 147 subjects | Genotype phenotype | Suggested relationship between polymorphism MTFR 677C → T and autism-related behaviours |
| [218]   | AGRE       | Blood and lymphoblasts | 693 subjects (AGRE) 5878 subjects (total) | CNV analysis | Microduplications and microdeletions in chromosome 16p11.2 associated with psychiatric disorders; duplications associated with schizophrenia, bipolar disorder and ASD, and deletions with ASD and other neurodevelopmental disorders. |
| [219]   | AGRE       | Blood             | 219 subjects | Variant analysis | DLX1/2 and DLX5/6 gene analysis may not contribute to ASD but functional analysis of variants still worth investigation. |
| [36]    | AGRE       | Blood             | 1410 (total) 401 (AGRE) | Association study | No association found for a sequence variant in mental retardation found in exon 1 of MECP gene in autism cohort. |
| [220]   | AGRE       | Blood and lymphoblasts | 112 families (total) 79 families (AGRE) | Association study | A haplotype for DRD1 is found to be associated with ASD risk amongst males. |
| [221]   | AGRE       | Data from [222]   | 551 subjects (AGRE) | SNP analysis | Analysis of SNPs revealed variants of CD38 associated with ASD. Variants of CD38 linked to control of OXT secretion. |
| [222]   | AGRE       | Lymphoblastoid cell | 14 subjects | Gene expression analysis | First study to show differential expression between lymphoblastoid cell lines. Genes affected implicated in cell death and development, nervous system development and immune development and function. |
| [224]   | AGRE       | Lymphoblasts      | 116 subjects | Gene expression analysis | Patients with severe ASD showed altered expression of genes involved in Circadian rhythm. 20 novel genes found putative non-coding regions associated with androgen sensitivity. |
| [225]   | AGRE       | Genomic data      | 1295 families (total) 696 families (AGRE) | GWAS | Noise reduction filter for GWAS leads to list of 830 candidate genes, where they impact dendrite and axon outgrowth and guidance. |
| [29]    | AGRE ATP   | Blood and brain   | 133 sib pairs (total) 77 Sib pairs (AGRE) | Oligogenic hypothesis study | Evidence of epigenetic and genetic factors possibly contributing to ASD and UBE3 having a possible role in ASD. |
| [179]   | AGRE       | Blood and lymphoblasts | 192 subjects (AGRE) 483 subjects (total) | Association study | Disruptions in NRXN1 gene found to be associated with ASD. |
| [226]   | AGRE       | Genomic data      | 474 subjects (total) 290 subjects (AGRE) | Association study | Suggestive association of parent and maternal origin effect on SLC6A4 promoter variant and ASD. Further testing required on biological model or larger cohort. |
| [26]    | AGRE       | Blood and lymphoblasts | 1549 subjects 410 subjects (AGRE) | Mutation screening | Recurrent microdeletions in chromosome region 16p11.2 were observed in ASD patients and not in controls. |
| [227]   | AGRE       | Blood and lymphoblasts | 974 subjects (total) 512 subjects (AGRE) | Mutation screening | RIMS3 identified as a possible ASD susceptibility gene. |
| [228]   | AGRE       | Blood             | 33 families (AGRE) 49 families (total) | Association study | Association found for HLA-DR4 gene in higher frequency in geographically defined subtype, but not in controls or AGRE sample. |
| Reference | Collection | Sample Size | Study Type | Findings |
|-----------|------------|-------------|------------|----------|
| [229] AGRE Blood | 508 families (total), 139 families (AGRE) | Association study | Analysis of 2p15-16.1 microdeletions region identified two candidate genes: XPO1 and OXT1 |
| [230] AGRE Blood and lymphoblasts | 407 families (total), 138 families | Association analysis | Polymorphisms found in or near DLX1 and DLX2 found to be associated with ASD |
| [231] AGRE Blood and lymphoblasts | 512 families (total), 138 families (AGRE) | Association study | Association found between ASD and MTHFR gene in simplex families but not in multiplex families |
| [237] AGRE Blood and lymphoblasts | 219 families (total), 98 families (AGRE) | Association study | Polymorphisms in MECP2 found to be associated with ASD |
| [232] AGRE Genomic data | 990 families | Association study | 2 genes found to be associated with ASD: RYR2 and UPP2 |
| [233] AGRE Genomic data | 2194 families (total), 543 families (AGRE) | Association study | Association found between the calcium channel genes (CACNA1L, CACNA1C and CACNA1A) with ASD |
| [234] AGRE Genomic data | 470 families (total), 224 families (AGRE) | Gene association studies | GABRA4 and GABRB1 found to be associated with ASD |
| [235] AGRE Genomic data | 680 families (AGRE), 1167 families (total) | GWAS | Identification of a common novel risk locus as chromosome region 5p14.1. Common and rare variants identified. AGRE used as validation dataset |
| [238] AGRE Blood and lymphoblasts | 276 families (AGRE), 17 subjects (ATP) | Association study | MARK1 gene found to be associated with ASD. Overexpression of gene also found in prefrontal cortex (BA46) but not cerebellum in human post-mortem tissue. Mouse model showed abnormalities in dendrites. |
| [239] AGRE Blood | 137 families (total), 80 families (AGRE) | Linkage analysis | Increased support that chromosome regions 19p13 and 17q11.2 harbour ASD susceptibility loci |
| [240] AGRE Blood and lymphoblasts | 1336 subjects (AGRE), 1509 subjects (total) | CNV analysis | Large-scale survey of 15q24 microdeletion syndrome identifies atypical deletion that narrows critical region and (776 kb versus 1.75mb) and number of genes (15 versus 38) sequencing of genes recommended |
| Study Ref. | Source & Sample Type | Sample Size | Methodology | Findings |
|-----------|----------------------|-------------|-------------|----------|
| [241]     | AGRE Genomic data    | 4278 subjects (total) 1518 subjects (AGRE) | Transmission disequilibrium testing | AGRE dataset found to have a genome-wide signals at chromosome region 10q26.13 in both sexes and paternal signals in 6p21.1 |
| [30]      | AGRE Blood and lymphoblasts | 2886 subjects (total) 1441 subjects (AGRE) | CNV analysis | Microdeletions and duplications at chromosome region 15q13.2q13.3 found to be associated with ASD symptoms and other psychiatric disorders |
| [242]     | AGRE Blood and Lymphoblasts | 34 subjects | Linkage analysis study | Chromosomes 7q and 21q are associated with a subset of ASD patients with developmental regression |
| [222]     | AGRE Blood and brain tissue | 1221 subjects (total) 263 subjects (AGRE) | Association study | Two genetic variants of CD38 found to be associated with ASD |
| [243]     | Blood                | 233 subjects | Association study | HOXA1 A218G alleles found to significantly influence head growth rates. |
| [244]     | AGRE Blood           | 196 families | Association study | Association not found between SNPs in DLX6 and PLCO on chromosome 7q21-22 and ASD |
| [245]     | AGRE Blood           | 196 families | Association study | Association not found between SNPs in DLX6 and PLCO on chromosome 7q21-22 and ASD |
| [246]     | AGRE Blood and lymphoblasts | 249 families | Association study | Presence of a susceptibility mutation found in TDO2 or nearby gene |
| [47]      | AGRE and ATP Lymphoblasts | 14 subjects (AGRE) 84 subjects (ATP) | Methylation study | Elevated levels of STX1A found to be associated with ASD |
| [247]     | AGRE Blood and lymphoblasts | 110 subjects | Genetic association study | Association found between PER1 and NPAS2 and ASD |
| [248]     | AGRE Blood and lymphoblasts | 104 families | Genetic association study | BDNF associated with ASD; significantly higher expression in ASD subjects |
| [249]     | AGRE Blood and lymphoblasts | 13,205 subjects (total) 80 subjects (AGRE) | CNV analysis | Disruption of the PTHCD1 locus on Xp22.11 identified in families with ASD and in families with intellectual disability. Novel CNVs identified in DPYD and DPP6. |
| [80]      | AGRE and ATP Lymphoblasts and brain tissue | 13 subjects (AGRE) 3 subjects (ATP) | Genotype-phenotype study | Increased dosage of the gene CYFIP1 results in altered cellular and dendritic morphology and dysregulates mTOR pathway in ASD patients with duplications in 15q11-13 |
| [250]     | AGRE Blood and lymphoblasts | 95 subjects (AGRE) 134 subjects (total) | Genomic and molecular study | No coding mutations or parental-specific expression found in ASD and Gilles de la Tourette syndrome (GTS) in the gene IMMP2L. Gene should not be written out as factor for both conditions |
| [251]     | AGRE Blood and lymphoblasts | 283 families | Linkage mapping study | PRKCB1 shown to be associated with ASD |
| [252]     | AGRE Blood and lymphoblasts | 1086 subjects | Candidate gene study | PITX1 shown to be associated with ASD |
| [253]     | AGRE Blood            | 406 families (total) 99 Families (AGRE) | Association and linkage disequilibrium study | GAD1 SNPs found not to be associated with ASD |
| [254]     | AGRE Blood            | 322 families (total) 86 families (AGRE) | Association study | No association found with APOE gene and ASD. |
| [255]     | AGRE Genomic data     | 4530 subjects | Association study | Immune function genes CD99L2, JARID2 and TPO show association with ASD |
| Reference | AGRE Type | Study Type | Study Details | Summary |
|-----------|-----------|------------|---------------|---------|
| [256]     | AGRE Blood and lymphoblasts | 334 families | Association study | Analysis of 2q24-q33 region found following genes associated with ASD, SLC25A12, STK39 and TGFα4. |
| [257]     | AGRE Blood and lymphoblasts | 411 families (total) 371 families (AGRE) | Linkage analysis | Linkage analysis of SNPs suggests SLC25A12 to be associated with ASD. |
| [258]     | AGRE Blood and lymphoblasts | 352 families | Association study | No association found between polymorphisms in TPH1 and TPH2 and ASD susceptibility or endophenotypes. |
| [259]     | AGRE Blood and lymphoblasts | 352 families (total) 295 families (AGRE) | Association study | No association found between SLC6A4 variants and susceptibility to ASD. |
| [260]     | AGRE Blood and lymphoblasts | 1011 subjects | Association study | AHI1, a gene associated with Joubert Syndrome, is also implicated in ASD. |
| [261]     | AGRE Genomic data | 2883 individuals | Methods paper | Tool that provides visualisation of SNP data. |
| [262]     | AGRE Serum | 34 subjects | Metabolite study | ASD patients had lower levels of the enzyme AAT in serum compared to controls. Difference is much more significant in ASD patients with regressive onset. |
| [263]     | AGRE Blood and lymphoblasts | 486 subjects (total) 252 subjects (AGRE) | Genotype-phenotype study | Mice with CADPS2 knockout display autistic-like behaviour and cellular features. Analysis of human Cadps2 mRNA revealed aberrant splicing that resulted in some patients lacking exon 3 of the transcribed gene. |
| [264]     | AGRE Blood and genomic data | 860 subjects (total) 468 subjects (AGRE) | GWAS | Regions in 5q21.1 and 15q22.1-q22.2 found to have most significant association in combined data for Asperger. 8 regions overlap with ASD linkage areas, and 3 overlapped with a Finnish cohort. |
| [79]      | AGRE Lymphoblasts | 14 subjects | MicroRNA analysis | Dysregulation of MicroRNA expression contributes to gene expression in ASD. Gene targets ID3 and PLK2 were validated by knockdown and overexpression assays. |
| [265]     | AGRE Genomic data | 289 families | Method paper | SNPs involved in three-way epistatic interactions found and all located in gene GPRK3. |
| [58]      | AGRE Blood and lymphoblasts | 264 families | CNV analysis | De novo CNVs were found to be strongly associated with Autism. |
| [266]     | AGRE Blood and lymphoblasts | 248 subjects (total) 146 subjects (AGRE) | Association study | Results suggestive that a y-chromosome haplotype effect is associated with ASD. |
| [267]     | AGRE Blood and lymphoblasts | 196 families | Transmission analysis | Polymorphisms in INPP1, PKG3 and TSC2 found to have linkage disequilibrium in ASD subjects. |
| [268]     | AGRE Blood and lymphoblasts | 196 families | Transmission analysis | Suggestive evidence that GRM8 is a susceptibility gene in ASD. |
| [269]     | AGRE Blood and lymphoblasts | 196 families | Association study | Suggestive but tentative evidence for MTF1 and SLC11A3 as ASD susceptibility genes. |
| [270]     | AGRE Blood and lymphoblasts | 10 subjects | Whole genome sequencing | 59 candidate genes suggested to be associated with ASD susceptibility, with ANK3 being the top result. 33 non-coding variants were also identified. |
| [271]     | AGRE Genomic data [73] | 1336 subjects | Method paper | CNV analysis method that uses both B-allele frequency and log R ratio to find CNVs. Found all 21 validated short duplications in AGRE dataset. Analysis is much faster. |
| [272]     | AGRE Blood and lymphoblasts | Data taken from Ramoz, 2004 | Association study | Data taken from Ramoz, 2004. |
Table 2 Overview of studies using the AGRE collection (Continued)

| Study | Organization | Tissue | Subjects | Study Type | Results |
|-------|--------------|--------|----------|------------|---------|
| [273] AGRE | Blood and lymphoblasts | 144 subjects | Sequencing study | Suggestive association found for ASD-related routines and rituals with a polymorphism in SLC25A12 |
| [274] AGRE | Blood | 351 families | Association study | 7 rare variants found in NLGN4X. UTR found not to be significant. 2 intronic variants suggested to influence regulation of genes. Limited by throughput and cost |
| [275] AGRE | Genomic data | 148 families | Linkage analysis | Nominal significance found for 15 genes, top 3 being MYO1D, ACC1, and LSAT1 suggested for further study |
| [276] AGRE | Lymphoblasts | 284 subjects | Association study | Male-specific linkage mapped to chromosome 17q11. Evidence of sex specific risk alleles in ASD |
| [277] AGRE | Blood | 100 subjects | Cholesterol metabolism | CACNAG identified as a candidate gene for ASD |
| [278] AGRE | Genomic DNA | 756 subjects | Association study | EGFR found to have significant association with ASD |
| [279] AGRE and ATP | Data mining (AGRE) brain tissue (ATP) and blood | 83 subjects | Linkage study | SLG6A4 shown to contribute to ASD susceptibility |
| [280] AGRE | Blood | 97 families | Expression profile analysis | Lymphoblastoid cell lines from ASD patients can be used to assess microRNAs in ASD. Dysregulated microRNAs found to target genes linked to ASD |
| [281] AGRE | Blood and lymphoblasts | 196 families (total) 95 families (AGRE) | Mutation screening | Screening of ASD patients found rare variants not present in controls |
| [282] AGRE | Blood and lymphoblasts | 136 families (total) 96 families (AGRE) | Expression profile analysis | No mutations found in coding regions of X-chromosomal NLGN genes. |
| [283] AGRE | Lymphoblasts | 11 subjects | Neurotoxicity | High association of FMR1 gene variant found amongst east Asian individuals, but not when whole sample was analysed; stratification confounded result |
| [284] AGRE | Blood, lymphoblasts and brain tissue | 1031 families (AGRE) 3104 families (total) 30 subjects (ATP) | GWAS | Both ASD patients and controls showed upregulation of heat shock proteins when expressed to thimerosal in blood and lymphoblasts |
| [285] AGRE | Lymphoblasts | 5675 subjects (AGRE) | Association study | Genome-wide SNPs found in CDH10 and CDH9 found to be associated with ASD |
| [286] AGRE and ATP | Data mining (AGRE) brain tissue (ATP) and blood | 1031 families (AGRE) 3104 families (total) 30 subjects (ATP) | Linkage study | Analysis found association in chromosome region 5q15, where genes SEMA5A and TASR2 are located. Analysis of brain tissue showed reduced expression of SEMA5A in ASD subjects |
| [287] AGRE | Lymphoblasts | 5675 subjects (AGRE) | Association study | Micro deletion found in chromosome 16p11.2, amongst AGRE, Boston Children's Hospital and Icelandic population data sets |
| Study Numbers | Type of Material | Participants | Study Type | Findings |
|---------------|-----------------|--------------|------------|----------|
| [57]          | AGRE Blood      | 229 families | Association study | Sodium channel genes SOX11-3 contained SNPs of interest amongst ASD families for future studies |
| [285]         | AGRE Blood      | 564 families (total) 327 families (AGRE) genetic analysis only 261 subjects (serotonin analysis) | Association study | ITGB3 genetic variation found to be associated with serotonin blood levels and ASD susceptibility |
| [286]         | AGRE Genomic data | 5328 subjects | Recurrence rate study | Significant difference in recurrence rates between male only families and female carriers in regard to ASD. Female protective effect suggested to be at work in high genetic-risk families involving female carriers. Shorter interbirth intervals correlated to ASD risk. |
| [287]         | AGRE Blood lymphoblasts | 1587 subjects | Linkage analysis | Replication of linkage on 20p13. Linkage found for chromosomes 6q27, 8q13.2, 1p31.3, 8p21.2 and v8p12 |
| [288]         | AGRE Lymphoblasts | 75 subjects (total) 50 subjects (AGRE) | Gene characterisation | Gene characterised and assessed for mutation amongst ASD patients. No concrete association found |
| [289]         | AGRE Genomic data | 487 families | Method paper | Pathways of interest analysed using GWAS SNP data. 5 pathways shown to be of significance in regards to ASD |
| [290]         | AGRE Blood and lymphoblasts | 383 subjects | Loci analysis | AGRE and Finnish ASD dataset both showed strong association with 3p24-26 locus containing the gene OXTR |
| [291]         | AGRE Blood and lymphoblasts | 833 families | Genome-wide screen | Evidence of linkage to ASD found on chromosomes 17, 5, 11, 4 and 8, of which 17 having the highest association score in the group |
| [292]         | AGRE Blood and lymphoblasts | 110 families | Genome-wide linkage analysis | Nominal evidence for linkage found in chromosomes 2-4, 8, 10-12,15-16,18 and 20. Significant linkage found for chromosomes 5 and 8 after reanalysis |
| [46]          | AGRE Blood      | 126 families (total) 81 families (AGRE) | Association study | No evidence found that RH-ABO foetal-maternal incompatibility is associated with ASD |
| [293]         | AGRE Blood and lymphoblasts | 165 subjects | Population genetics | No association found between ASD and variant of the gene EN2 |
| [294]         | AGRE Blood and lymphoblasts | 205 families | Gene association study | No association found between ASD and variant of the gene EN2 |
| [295]         | AGRE Lymphoblasts | 20 subjects | Intracellular redox study | Inbalance of glutathione redox in cell lines derived from patients with ASD |
| [76]          | AGRE Lymphoblasts | 86 subjects | Transmethylation/ transsulfuration study | Cell lines derived from parents of ASD children showed abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation |

Study numbers listed as families or subjects wherever applicable.
| Reference | Bio-collection | Samples                              | Number       | Study                     | Findings                                                                                                                                                                                                 |
|------------|----------------|---------------------------------------|--------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [296]      | SSC            | Genomic data                          | 2760 subjects| CNV analysis              | No association found between conception-assisted reproduction and risk of ASD                                                                                                                             |
| [297]      | SSC            | Lymphoblasts                          | 900 subjects | Sequencing study          | Rare functional variants of TSC1/TSC2 did not show association with ASD                                                                                                                                   |
| [298]      | SSC            | Genomic data                          | 965 subjects (SSC) | Integrative analysis      | Integrative analysis of data from 4 exome sequencing studies revealed enrichment of genes involved in chromatin remodelling and transcription in ASD patients                                                     |
| [298]      | SSC            | Blood                                 | 3730 subjects| Genotype-phenotype study  | Subtype of autism was caused by mutations to CHD8, of which 15 were found.                                                                                                                               |
| [299]      | SSC            | Blood                                 | 259 subjects  | CNV analysis              | Paired duplications mark cryptic inversions and other complex structural variations in CNV data.                                                                                                          |
| [300]      | SSC            | Blood                                 | 552 subjects (total) 412 subjects (SSC) | Transcriptome analysis | Neuron development, nitric oxide signalling, neurogenesis and skeletal development were found outliers amongst ASD patients in TGEN cohort, whereas outliers were found in neurogenesis in ASD patients from SSC cohort |
| [301]      | SSC            | Blood and lymphoblasts                | 99 families   | CNV analysis              | 55 potential pathogenic CNVs were identified and validated. 20% were considered rare when compared to the database of genomic variants. CNVs found in lymphoblast DNA but not in blood, suggesting pre-existing mutations may have been present in initial lymphoblast cells |
| [302]      | SSC, AGRE      | Blood and urine                       | 12600 subjects (total) 1887 subjects (SSC) 752 subjects (AGRE) | Association study | TMLHE found to have high levels of deletion in male-male multiplex families (1 in 190) and deficiency of this gene could be a susceptibility factor for ASD.                                                                 |
| [303]      | SSC            | Genomic and exomic data               | Taken from earlier studies [60, 61, 70] | Genotype-phenotype study | Mutations in ASD candidate genes have greatest impact on pyramidal neurons, cortical neurons and medium spiny neurons. Truncating de novo mutations play a small role in high-functioning cases. The greater the functional disruption of genes, the more severe the phenotypes are. |
| [304]      | SSC            | Blood                                 | 2575 subjects  | GWAS                      | Reducing phenotypic heterogeneity within the cohort did not have a significant effect on increasing genetic homogeneity.                                                                                   |
| [305]      | SSC, AGRE      | Blood                                 | 14989 subjects (total) 5981 subjects (AGRE) 1815 subjects (SSC) | GWAS                      | CNVs found in SEMA5 regulated gene network found to be associated with ASD                                                                                                                                |
| [306]      | SSC            | Blood                                 | 13,804 subjects | WES                       | 104 genes were implicated in 5% of ASD cases, where they are involved in transcription, chromatin remodelling and synapse formation.                                                                 |
| [307]      | SSC            | Blood                                 | 2963 subjects  | WES                       | De novo INDELS primarily originate from father, frameshift INDELS associated with ASD, Frameshift INDELS more frequent in females, RIMS1 and KMT2E found to be associated with ASD                                        |
| [308]      | SSC            | Blood                                 | 8 subjects     | Methods Paper             | WGS data more effective than WES for detection of INDELS. x60 sequencing required to recover 95% of detected Indels                                                                                      |
| [309]      | SSC            | Genomic data                          | 2066 subjects  | Homozygosity study        | In ASD simplex families, increased runs of homozygosity is associated with Intellectual disability                                                                                                     |
| [310]      | SSC            | Blood                                 | 1227 subjects (total) 350 subjects (SSC) | CNV analysis              | CNV burden correlates to certain disorders; high CNV burden to Intellectual disability and low CNV burden to dyslexia                                                                                   |
| [311]      | SSC, AGRE      | Blood                                 | 3168 subjects (total) 2478 subjects (SSC) 719 subjects (AGRE) | Rearrangement hotspot study | 1q21 duplications found to be associated with Autism. CNVs identified in CHD1L, ACACA, DPP10, PRC1, TRPM1, NRXN1, FHT and HYDIN enriched in ASD. Duplications linked to decreased non-verbal IQ and duplications linked to severity of ASD. |
| Study | Collection | Type | Subjects | Method | Description |
|-------|------------|------|----------|--------|-------------|
| [149] | SSC IPSCs and lymphoblasts | 1041 | Disease modelling study | Disruption of TRPC6 causes disruption in human neurons and linked to a non-syndromic form of ASD. First Study to use Patent-derived IPSCs to model non-syndromic form of ASD. | |
| [309] | SSC AGRE Blood | 2975 | GWAS sequencing | Rare variants in synaptic genes associated with ASD. Loss of function in candidate genes a major risk factor for ASD. | |
| [310] | SSC TASC Blood | 932 families | Method paper | Transmission and de novo association (TADA) is a method that incorporates WES data, as well as inherited variants, and variants identified between cases and controls. | |
| [311] | SSC Exome data | 597 | Method description | Association was found between ASD and rare variants of the gene ABCA7 in exome data. | |
| [312] | SSC Blood | 15479 | Transmission analysis | Demonstration that high and low IQs could be distinguished by LGD load in respective gene targets. Transmission of rare variants with low LGD load occurs more often to affected offspring. Biased transmission towards children with low IQ. | |
| [313] | SSC Blood | 1478 | WES | Gene disrupting mutations were twice as frequent in ASD subjects compared to controls. Genes disrupted were associated with Fragile X Protein FMRP. | |
| [314] | SSC Blood | 2106 | Common variation study | Multiple common variants of genes additively contribute to ASD risk. Simplex families found to closely follow additive model compared to multiplex families. | |
| [315] | SSC Blood | 285 | Transcriptomic study | Enriched genes found in long term potentiation/depression, Notch signalling and neurogenesis amongst ASD Patients. SS gene prediction model performed well on male subjects, but not female subjects. | |
| [316] | SSC Blood | 58 | Transcriptomic study | Upregulation of spliceosome, mitochondrial and ribosomal pathways and downregulation of neurotransmitter-ligand, immune response and calcium signalling pathways in ASD patients compared to controls. | |
| [317] | SSC Genomic data | 78349 | SNP study | 17–29% of variance in liability explained by SNPs. Genetic correlation found between disorders; High: Schizophrenia and bipolar disorder, Moderate: Schizophrenia and major depressive disorder, major depressive disorder and ADHD, major depressive disorder and bipolar disorder, Low: Schizophrenia and ASD. | |
| [60] | SSC Genomic Data | 1784 | CNV study | De novo duplications and deletions are major contributors to ASD. Females shown to have a greater genetic resistance to autism. | |
| [318] | SSC AGRE TASC Blood | 6970 | WES | 2-fold enrichment of complete knockout of autosomal genes with low LoF variation, and 1.5-fold enrichment for rare hemizygous knockout in males. Both contribute 3% to ASD risk, respectively. | |
| [319] | SSC Lymphoblasts | 386 | CNV study | Recurrent and rare de novo CNVs were discovered to alter gene expression in chromosome regions 3q27, 3p13, 3p26, 2p15, 16p11.2 and 7q11.23. | |
### Table 3 Overview of studies using the SSC collection (Continued)

| Reference | Collection | Sample Size | Study Type | Description |
|-----------|------------|-------------|------------|-------------|
| [129]     | SSC        | 12 subjects | Disease modelling | Overexpression of FOXG1 was linked to increased head circumference and ASD severity in idiopathic autism subjects. An overabundance of inhibitory neurons in ASD cell lines was also found. |
| [319]     | SSC        | 2478 subjects | Gene-environment study | Individuals with ASD-associated CNVs were more susceptible to effects of febrile episodes and maternal infection during pregnancy and have an impact on behavioural outcomes |
| [320]     | SSC        | 10118 (TOTAL) 1974 (SSC) | Genetic association | Higher prevalence of SLC12A5 variants containing altered CpG sites amongst ASD patients. |
| [321]     | SSC, DNB   | 2418 subjects (SSC) 1353 subjects (DSNB) | CNV analysis | 17q12 deletion identified as a CNV variant that confers high risk of ASD and Schizophrenia |
| [322]     | SSC, AGRE  | 49167 subjects (total) 1124 subjects (SSC) 1835 subjects (AGRE) | CNV analysis | More significant CNVs that could infer ASD risk were identified using combined large clinical datasets of neurodevelopmental disorders than with ASD cohorts alone |
| [323]     | SSC        | 5451 subjects | Association study | No association found for heterozygous mutations in CNTNAP2 and contribution to ASD risk |
| [324]     | SSC        | 593 families | Method description | A novel method was used to detect de novo and transmitted insert-deletions (Intel's) in exomic data |
| [325]     | SSC        | 1315 subjects (total) 145 subjects (SSC) | CNV analysis | Duplication CNVs enriched in negative regulation categories, deletion CNVs enriched in positive regulation categories. Highly connected genes in network enriched in patients with a single gene CNV change |
| [326]     | SSC        | 677 subjects (SSC) | WES | De novo mutations paternal in origin (4:1) and positive correlation with age. Recurrent mutations in genes CDH8 and NTN1/1. |
| [327]     | SSC        | 20 families (total) 19 families (SSC) | WES | 21 de novo mutations identified. 11 of which found to be protein altering. Mutations identified in FORP1, GRIN2B, STX1A, LAMC3 and CNTPAP2. |
| [328]     | SSC, DNB   | 2246 subjects (SSC) | WES | 27 de novo events found in 16 genes, 59% predicted to truncate proteins. Further support for genotype-phenotype relationship in CDH8 and Dyrk1a |
| [329]     | SSC, AGRE  | 19 subjects (total) 4 subjects (SSC) | Genotype-phenotype | Overexpression/increased dosage of MECP2 related with core features of ASD |
| [330]     | SSC        | 8816 subjects (total) 737 subjects (SSC) 4449 (AGRE) | Replication study | Findings could not be replicated from Skafidas paper |
| [331]     | SSC, DNB   | 38000 subjects (total) 4358 subjects (SSC) 19142 subjects (DSNB) | General population study | Genetic influences on ASD risk found to influence typical variation in social and communication ability in the general population |
| [332]     | SSC        | 2256 subjects | De novo and familial influences | Familial influences were more significant in cases of high-functioning ASD conditions. |
| [333]     | SSC, AGRE  | 1 subject | Clinical report | De novo microdeletion in chromosome 3q29 associated in person with ASD, childhood psychosis and intellectual disability |
| [334]     | SSC        | 1024 families | De novo mutation analysis | Significant role for loss of function mutations in ASD cases. |
| Study Number | Collection | Assay | Biomedical Approach | Findings |
|--------------|------------|-------|---------------------|----------|
| [329]        | AGRE       | Blood | Predictive testing  | Diagnostic classifier containing 237 SNPs and 146 genes |
|              | SSC        |       |                     |          |
| [330]        | SSC        | Blood | Genotype-phenotype study | NPAS1 found to repress generation of specific subtypes of cortical interneurons |
|              | AGRE       |       |                     |          |
| [85]         | SSC        | Blood | Whole genome sequencing | Enrichment of disruptive mutations in putative regulatory regions in ASD patients |
| [71]         | SSC        | Blood | Genotype-phenotype study | Disrupting mutations in Dyrk1a were linked to a subset of 15 patients with a syndromic form of ASD/ID. |
| [331]        | SSC        | Blood | WES                 | Enrichment of non-synonymous and potentially pathogenic mutations in mitochondrial DNA in ASD patients compared to controls. Transmission of potential pathogenic mutations differed between mother-ASD pairs and mother-sibling pairs |
| [332]        | SSC        | Lymphoblasts | Mutation analysis | PKA found to be an upstream regulator of UBE3A, where mutation in phosphorylation site results in hyperactivity of UBE3A |
| [333]        | SSC        | Blood | WES                 | Bi-allelic mutations found in genes enriched in inherited ASD cases (AMT, PEX7, SYNE1, VPS13B, PAH, POMGNT1) |
| [334]        | SSC        | Blood | WES                 | Strong evidence that de novo mutations are associated with ASD |
| [69]         | SSC        | Blood, lymphoblasts and saliva | CNV analysis | Significant associations found between ASD and de novo duplications of chromosome 7q11.23. de novo CNVs identified in 5 other regions, including 16p13.2 |
| [335]        | SSC        | Genomic data | Transmission disequilibrium | De novo CNVs associated with ASD. 6 loci and 65 genes identified, many targeting the chromatin or synapse |
| [336]        | SSC        | Genomic data | Transmission disequilibrium | Excess of truncating inherited mutations associated with ASD. RIM51, CUL7, LTZR1 identified as candidate genes |
| [312]        | SSC        | Genomic data | Biased transmission study | Affected ASD patients inherited more CNVs than their unaffected siblings, and these CNVs of ASD patients affected more genes. Enrichment of brain-specific genes in inherited CNVs amongst ASD patients |

Study numbers listed as families or subjects wherever applicable.
in a subset of ASD with altered brain size, distinct facial features and gastrointestinal complaints. Disruption of CDH8 in zebra fish recapitulated some of the patient phenotypes including increased head size and impaired gastrointestinal motility [88]. CHD8 is shown to control expression of other high-confidence de novo ASD risk genes such as DYRK1A, GRIN2B and POGZ [89]. Mutation of DYRK1A was strongly linked to a subset of ASD patients with seizures at infancy, hypertonia, intellectual disability, microencephaly, dysmorphic facial features and impaired speech [71, 89]. POGZ gene which plays a role in cell cycle progression is also found to contribute to a subset of ASD with varying developmental delay, vision problems, motor coordination impairment, tendency of obesity, microcephaly, hyperactivity and feeding problems [90].

Danish Newborn Screening (NBS) Biobank
The NBS Biobank has a large collection of dried blood spot samples (DBSS), which are taken from new-borns 5–7 days after birth. They are sent to the Newborn Screening lab at the Statens Serum Institute for analysis, and stored at –20 °C in a separate freezing facility at the NBS Biobank. Prior to collection, parents are informed via leaflets about the biobank, with focus on what the samples will be used for (documentation, testing and retesting, research, etc.). Participants can opt out of storage at any time via a letter to the department. For security, both the clinical data and biological samples are linked via a unique number, kept in separate buildings, and are accessible by authorised personnel only [91]. The advantage of the NBS resources is that it provides a large amount of non-ASD controls as well as Danish ASD samples.

In the past 30 years the NBS Bio-collection has accumulated samples from 2.2 million individuals, around 65,000–70,000 samples per year from Denmark, Greenland and the Faroe Islands. Most recently this resource has been included under the Danish iPsych consortium with the Psychiatric Genomics Consortium (PGC), added 8–12 k samples to the PGC analysis and significantly increased its power to detect common genetic effects for ASD, which have been recently published [92]. DBSS were also used to examine metabolites. A group led by Abdallah carried out a series of studies on Danish collections (Table 4) to examine the potential role of cytokines and chemokines involved in signalling and immune response of ASD. Initially using amniotic fluid from the Danish Birth Cohort (DBC) collection [93, 94], they followed up with DBSS from new-borns crossed referenced from that cohort [95, 96]; they detected an imbalance of cytokines amongst ASD subjects compared to the controls. Most of the chemicals were lower than normal, such as Th-1 and Th-2 like cytokines involved in proliferation, priming and activation of these cell types, whereas a small number of cytokines displayed increased expression in ASD. The abnormal levels of these chemicals could lead to a hypoactive or “inactive” immune system in the brain, making it more susceptible to infection-related ASD. However, when chemokine levels were examined in amniotic fluid, no concrete relationship could be established.

The Autism Simplex Collection (TASC)
TASC is a trio-based international bio-collection that was assembled in collaboration with the Autism Genome Project and funded by Autism Speaks [97]. Trios, comprised of both parents and a child affected with ASD with no known medical or genetic cause. Collection of samples took place between 2008 and 2010 across 13 sites; 9 in North America and 4 in Europe. Management, storage and distribution of TASC data are handled by the Centre for Collaborative Genetic Studies on Mental Disorders (CCGSMD) [97]. Samples are housed at the NIH and AGRE repositories both of which are located at Rutgers University.

So far, TASC has been used for GWAS studies [66] and CNV studies [72, 98, 99] and WES Studies [16, 100, 101]. In addition, TASC has also been used in WGS as part of the MSSNG project, which is discussed below.

Autism Inpatient Collection (AIC)
The AIC is a bio-collection for ASD research based on those on the severe end of the spectrum with severe language impairment, intellectual disability and self-injurious behaviour. This collection was founded on the basis that this segment of ASD patients are largely unrepresented in current studies. Bio-samples are initially recruited from 147 patients, and ongoing recruitment is estimated at 400 per year. Psychiatric, clinical and phenotypic data are collected in addition to blood samples for the creation of lymphoblastoid cell lines by RUCDR. Amongst this collection, over half are non-verbal, over 40% have intellectual disability and a quarter exhibit self-injurious behaviour [24]. This collection has yet to be used in any genetics-based studies. The fact that many patients are on the severe end of the spectrum makes it a welcome addition, and it opens opportunities to explore this under-represented group.

Autism Tissue Program (ATP)/Autism BrainNet
The Autism Tissue Program, now the Autism Brain Network, is a post-mortem ASD brain collection coordinated by a network of parents, caregivers, physicians and pathologists. Brain samples are preserved in formalin and/or in −80 °C freezers to maximise the potential studies. In some cases, both hemispheres are fixed in
formaline when there is freezing capacity or if the post-mortem interval exceeds 24 h. Corresponding clinical data include age, sex, ethnicity, diagnosis, brain size, cause of death, post-mortem interval and preservation method for the left and right hemisphere of the brain. Due to the rarity of the sample, a thorough application procedure assesses scope, scale and feasibility of proposed projects prior to access of tissue, with the expectation that data, images and presentations generated by research on the samples are provided back to the Autism Brain Network 3 months after formal release of publications [102].

Brain pathology and molecular mechanisms have been the focus of studies using the ATP resource (Table 5) although many studies looking at brain anatomy and cell morphology employed samples from this collection, molecular and genetic studies are the primary focus of this review. Such studies included transcriptomics [103–105], epigenetics [29, 106–115] and alternative splicing [116, 117]. A key discovery was the identification of convergent molecular pathology linking to neuronal, glial and immune genes [105] in a transcriptomics study that investigated the gene co-expression network between autistic and control brains. This led to the proposal of abnormal cortical patterning as an underlying mechanism due to attenuated differential expression in frontal and temporal cortices in ASD brains.

A recent study showed reduced Vitamin B12 in ASD brains [118] where the ATP made a very large contribution. Post-mortem examination of brain tissue ranging from foetal to the elderly subjects also showed a marked decline of the brain vitamin B12 with age, together with lower activity of methionine synthase in the elderly, but the differences were more pronounced in ASD and schizophrenia subjects when compared to controls. Acetylation is an important post-translational modification in the field of epigenetics. ATP also made a significant contribution to a large-scale histone acetylyme wide association study (HAWAS) using the prefrontal cortex, cerebellum and temporal cortex in ASD patients and controls. Despite their heterogeneity, 68% of syndromic and idiopathic ASD cases shared a common acetylyme signature at >5000 cis-regulatory elements in the prefrontal cortex and temporal cortex. Aberrant acetylyme was found to be associated with synaptic transmission, ion transport, epilepsy, behavioural abnormality, chemokinesis, histone deacetylyme and immunity [113].

The ATP sample was used in a methylation study that investigated differential methylation in CpG loci in three brain regions: temporal cortex, dorsolateral prefrontal cortex and cerebellum. Differential methylation of four genes (PRRT1, C11orf21/TSPAN32, ZFP57 and SDHAP3) was detected. PRRT1, C11orf21/TSPAN32 were hypomethylated while the latter two were hypermethylated [109]. A further investigation in Brodmann’s area also found a pattern of hypomethylation of a number of genes including C11orf21/TSPAN32 that are implicated in immune function and synaptic pruning [111]. These hypomethylated genes correlated with those showing overexpression by Voineagu.

The methylation studies have further uncovered dysregulation of OXTR and SHANK3 genes in ASD. OXTR gene encoding oxytoxin receptor was significantly hypermethylated in the peripheral blood cells and temporal cortex of ASD, highlighting a reduced oxytocin signalling in the aetiology of ASD [108] and a therapeutic target of ASD. Differential methylation of the SHANK3 gene was detected between ASD and control brains. They found that when three 5’ CpG islands of the gene were examined, they observed altered methylation also changed SHANK3 splicing, with specific SHANK3 isoforms expressed in ASD [114].

This is echoed by a recent study, which reveals a dynamic microexon regulation associated with the remodelling of protein-interaction networks during neurogenesis. The neural microexons are frequently dysregulated in the brains of ASD, which is associated with reduced expression of SRRM4 [116]. The neuronal specific splicing factor A2BP1/FOX1 and A2BP1-dependent splicing of alternative exons are also dysregulated in ASD brain [105].

**Replication studies and pooling resources**

Research data from one bio-collection is not always replicable in another sample set. Therefore, cross-validation between different bio-collections will not only minimise false positive, but also identify the common risk factors and subset-specific factors. For example, a genome-wide survey was carried out to test trans-generational effects of mother-child interactions, and the AGRE and SSC samples were used to replicate the original findings of 16 ASD risk genes (PCDH9, FOXP1, GABRB3, NRXN1, RELN, MACROD2, FHIT, RORA, CNTN4, CNTNAP2, FAM135B, LAMA1, NFIA, NLGN4X, RAPGEF4 and SDK1) involving urea transport and neural development. The results from the AGRE and SSC cohorts did not match the original study and showed fewer associations. When post-correction of the statistics was applied, the results lost their significance [119]. This could partially be due to the differences in the array design with different coverage of SNPs and/or different methodologies.

The meta-analysis of five data sets including the AGRE and SSC demonstrates that females have a greater tolerance to CNV burden. This leads to a speculation that the maternal tolerance of the CNVs can result in decreased foetal loss amongst females compared to males, and that ASD-specific CNV burden contributes to high
sibling occurrence. What is interesting about this study is that the results for high CNV burden in females are consistent throughout each data set. This is an example showing how multiple bio-collections can give a clearer picture in a combined study where individual studies may be ambiguous [120, 121].

Many major studies on the genetics of ASD have also been accomplished as a result of the collaborations amongst the institutions (Tables 2, 3, 4, 5 and 6). An effort was made to evaluate the association of Fragile X Mental Retardation 2 locus (AFF2) with ASD using joint resources from AGRE (127 males) and SSC (75 males). AFF2 encodes an RNA-binding protein, which is silenced in Fragile X. The study found that 2.5% of ASD males carry highly conserved missense mutations on AFF2 gene which was significantly enriched in ASD patients, when compared to >5000 unaffected controls [122]. A WES was published recently, which sequenced the exomes of over 20,000 individuals, including those from the SSC and Swedish registries. The study identified 107 candidate genes, and reinforced ASD pathways involved in calcium- (CACNA2D3 transcription. This study detected mutations in genes involved in synaptic formation, chromatin remodelling and gene transcription. This study detected mutations in genes involved in calcium- (CACNA2D3, CACNA1D) and sodium-gated channels (SCN2A) which were related to neuronal function, and in genes involved in post-translational methylation (SUV420H1, KMT2C, ASH1L, SETD5, WHSC1) and demethylation (KDM4B, KDM3A, KDM5B, KDM6B) of lysine residues on histones which provided molecular basis linking to neuronal excitation and epigenetic changes in ASD [86].

Multiple bio-collections were employed to investigate SHANK1, 2 and 3, which are scaffolding proteins implicated in ASD. They devised a genetic screen and meta-analysis on patients and controls including cohorts from the AGRE, SSC and Swedish twin registry. In total, ~1% of all patients in the study had a mutation in this group of genes. The mutations in SHANK3 had the highest frequency (0.69%) in patients with ASD and profound intellectual disability, SHANK1 (0.04%) and SHANK2 (0.17%) mutations occurred less frequently and were present in individuals with ASD and normal IQ, and ASD with moderate intellectual disability [123].

Recently Autism, Speaks, in coordination with Google and Genome Canada, have launched another initiative; MSSNG (https://www.mss.ng/). The objective of the MSSNG project is whole genome sequencing of 10000 genomes of families affected by ASD. This incorporates AGRE along with other bio-collections to sequence the entire genomes of families with autistic children, and as of the summer of 2016, it has reached the halfway goal of 5000 genomes out of 10000, with the contribution of the AGRE (1746) and TASC (458). Two studies have been published from this initiative. In the first study, genomes from 200 families were sequenced [124]. The findings revealed many of the de novo mutations (75%) from fathers, which increased dramatically with paternal age. Clustered de novo mutations however were mostly maternal origin, and located near CNV regions subject to high mutation. The ASD genomes were enriched with damaging de novo mutations, of which 15.6% were non-coding and 22.5% genic non-coding, respectively. Many of the mutations affected regulatory regions that are targeted by DNase 1 or involved in exon skipping [124]. The second study [125] featured 5205 sequenced genomes with clinical data, where an average of 73.8 de novo single nucleotide variants and 12.6 insertions/deletions/CNVs were detected per ASD patient. Eighteen new genes were also discovered (CIC, CNOT3, DIP2C, MED13, PAX5, PHF3, SMARCC2, SRSF11, UBN2, DYNC1H1, AGAP2, ADCY3, CLASP1, MYOSA, TAF6, PCDH11X, KIAA2022 and FAM47A) that were not reported in ASD previously. These data clearly demonstrate that ASD is associated with multiple risk factors, and within an ASD individual, and multiple genetic alterations may be present. The Whole genome sequencing is therefore a powerful tool to detect genetic changes at all levels. Resources like MSSNG are valuable, and pooling of ASD bio-collections are essential for identification of the common and subgroup-specific

| Reference | Bio-collection | Samples | Number | Study | Findings |
|-----------|----------------|---------|--------|-------|----------|
| [136]     | DNSB           | DBSS    | 1100 subjects | Chemokine analysis | Analysis of crude estimates showed decreased levels of RANTES. Adjusted estimates showed no significance amongst 3 chemokines studied (RANTES, MCP-1, MIP-1A). Cautious suggestion of altered immunity in neonatal period amongst ASD patients |
| [96]      | DNSB           | DBSS    | 1200 subjects | Cytokine analysis | Suggestive evidence of decreased levels of certain th-1 and th-2 like cytokines in newborns later diagnosed with ASD |
| [136]     | DNSB           | DBSS    | 1029 subjects | Neurotropic factor analysis | Decreased level of neurotropic factors found in ASD patients during Neonatal period |

Study numbers listed as families or subjects wherever applicable
| Reference | Bio-collection | Samples | Number | Study | Findings |
|-----------|----------------|---------|--------|-------|----------|
| [337]     | ATP and AGRE   | Brain tissue, blood and lymphoblasts | 18 subjects (ATP) 841 families (AGRE) 1029 families (total) | Gene expression and association analysis | Altered expression of mitochondrial genes in anterior cingulate gyrus, motor cortex and thalamus of ASD patients. Polymorphisms in MTX2, NEFL and SLC25A27 found to be associated with ASD. |
| [338]     | ATP            | Brain tissue | 18 subjects | Gene expression analysis | Reduced expression of several genes related to electron transport in anterior cingulate gyrus, motor cortex and thalamus of ASD patients |
| [339]     | ATP            | Brain tissue | 57 subjects | Functional genomic study | Analysis of CNVs showed differences of what pathways are altered between children and adults; cell number, cortical patterning and differentiation in the former, and signalling and repair pathways in the latter. Prefrontal cortex samples were used. |
| [106]     | ATP            | Brain tissue | 33 subjects | GWAS | Patients with ASD had more genes that were up- or down-regulated in an individual specific manner when prefrontal cortex tissue was examined |
| [340]     | ATP            | Brain tissue | 126 subjects (total) 42 subjects (ATP) | Sequencing study | Recurrent deleterious mutations found in ARID1B, SCN1A, SCN2A and SETD2. Higher proportion of mutations that are deleterious, protein-altering or cause loss-of-function in ASD patients compared to controls. Cortical and cerebellar tissue was used. |
| [107]     | ATP            | Brain tissue | 25 subjects | Deep sequencing study | Altered adenosine to inosine editing found in cerebellar tissue from ASD patients. Dysfunctional for of editing enzyme ADAR1 more frequently in ASD Cerebella |
| [341]     | ATP            | Brain tissue | 28 subjects (ATP) 43 subjects (total) | Gene expression analysis | Signalling partners of FMRP and GRMS (HOMER1, APP, RAC1, STEP) shown to have altered expression in the cerebellar vermis and superior frontal cortex in ASD patients compared to controls. |
| [342]     | ATP            | Brain tissue | 19 subjects | mRNA analysis | Reduction of multiple GABA receptor subtypes (A6, B2, D, E, G2, T and P2) detected in cerebellar vermis and superior frontal cortex ASD patients |
| [343]     | ATP            | Brain tissue | 25 subjects | Assay study | Imbalance in isoforms of precursor BDNF protein found in fusiform gyrus of ASD patients |
| [103]     | ATP            | Brain tissue | 18 subjects | Transcriptional and epigenetic association analysis | Downregulation of genes related to oxidative phosphorylation and protein translation. Associations were found between specific behaviour domains of ASD and gene expression modules related to myelination, immune response and purinergic signalling. Cerebral and Brodmann area 19 tissue was used. |
| [108]     | ATP            | Brain tissue | 16 subjects | Methylation study | Increased methylation was found for the gene OTX2 in ASD patients in blood and DNA from the temporal cortex |
| [104]     | ATP            | Brain tissue | 107 subjects | Transcriptome analysis | Dysregulated gene expression associated with glial cells shown to have negative correlation with gene expression relating to synaptic transmission in ASD patients when Brodmann areas 10, 19 and 44 were analysed |
| [344]     | ATP            | Brain tissue | 32 subjects | Transcription analysis | RORA may have dimorphic effects on gene expression in certain areas of cortical tissue between genders, and deficiency appears to cause greater gene dysregulation amongst males in both mice and humans |
| Study ID | ATP | Tissue Type | Subjects/Groups | Analysis Type | Findings/Comments |
|---------|-----|-------------|----------------|--------------|------------------|
| [345]   | ATP | Brain tissue | 30 subjects | Transcription analysis | αPP25 expression is decreased in the prefrontal cortex of ASD patients. |
| [116]   | ATP | Brain tissue | 23 subjects | Alternate splicing analysis and discovery | A conserved group of microexons involved in modulation of interaction domains of proteins and neurogenesis is disrupted in patients with ASD. |
| [29]    | ATP | Brain tissue | 17 subjects | Methylation study | UBE3 implicated as a contributing gene to autism and Angelman syndrome. |
| [346]   | ATP | Brain tissue | 20 subjects | Anti-sense RNA study | Discovery of anti-sense non-coding RNA that binds to moesin at 5p14.1 in ASD cerebral cortex tissue. |
| [109]   | ATP | Brain tissue | 40 subjects | Methylation study | 4 differentially methylated regions; 3 in temporal cortex and 1 in cerebellum. 3/4 regions were again found in different samples and brain regions. |
| [117]   | ATP | Brain tissue and lymphoblasts | 36 subjects (total) | Transcription and alternative splicing study | Accelerated decrease of MS gene transcription across ageing found in ASD patient cerebral cortex samples. |
| [347]   | ATP | Brain tissue | 73 subjects | Methylation study | Correlation found between reduced expression of MECP2 and increased methylation on the promoter region. |
| [110]   | ATP | Brain tissue | 24 subjects | Methylation study | Hypomethylation of mir142 and upregulation of mi-RNAs targeting OXTR gene in prefrontal cortex of ASD brains. |
| [348]   | ATP | Brain tissue | 24 subjects | Signal transduction study | Downregulation of PI3K-Akt genes observed in fusiform gyrus tissue of ASD patients. Similar effects noted in rat brain tissue exposed to valproic acid. |
| [349]   | ATP | Brain tissue (ATP) neuronal cells | 6 subjects | CHIP study | RORA found to regulate ZBP1, CYP19A1, HSD17B10, ITPR1, MEIWI and NTRR2 via transcription. Low levels of RORA causes dysregulation of these genes and associated pathways. Prefrontal cortex and cerebellum tissue was used. |
| [350]   | ATP | Brain tissue (ATP) | 153 families (other) 54 subjects (ATP) | Functional characterisation study | Variant of the HTR2A gene rs6311 in ASD patients has lower level of expression and contains extended 5′ untranslated region. Speculation that this variant could be a risk factor in ASD. Frontopolar cortex tissue was used. |
| [351]   | ATP | Brain tissue | 28 subjects | Micro-RNA study | Difference in pattern of micro-RNA expression between ASD superior temporal gyrus samples and controls. Further evidence that Mir-320, Mir-132 and Mir-322 are involved in ASD. |
| [113]   | ATP | Brain tissue | 94 subjects (total) 51 subjects (ATP) | Acetylome study | Common acetylome signatures found amongst 68% of ASD cases in 5000 regulatory regions in the prefrontal and temporal cortex. Acetylome profiles were not affected by SNPs at these regulatory regions. |
| [352]   | ATP and AGRE | Brain tissue, blood and lymphoblasts | 21 subjects (ATP) 252 families (AGRE) | Association study | Variants of LMX1B show modest association with ASD. Analysis of mRNA from anterior cingulate gyrus is much lower in ASD patients compared to controls. |
| [105]   | ATP | Brain tissue | 36 subjects | Gene co-expression network analysis | Transcriptional and splicing dysfunction implicated in disorder. Enrichment for genes in glial, immune and neuronal modules. Gene A2BP1 linked to alterations in splicing. Studies based on using temporal cortex, frontal cortex and cerebellum. |
Table 5 Overview of studies using the ATP/Autism BrainNet collection (Continued)

| Study   | Source | Tissue | Subjects | Analysis | Description |
|---------|--------|--------|----------|----------|-------------|
| [353]   | ATP    | Brain tissue | 28 subjects (total) 8 subjects (ATP) | Gene expression analysis | Genes expressed at higher levels in males enriched in upregulated genes in post-mortem neocortical tissue in ASD patients, including astrocyte and microglia markers |
| [118]   | ATP    | Brain tissue (ATP) and placenta | 12 subjects (ATP) 64 subjects (total) | Vitamin B12 study | Reduced levels of B12 found in ASD, aged and Schizophrenic patients compared to controls, oxidative stress found in ASD and Schizophrenia patients. Frontal cortex tissue was used |
| [114]   | ATP    | Brain tissue | 98 subjects | Methylation study | Altered methylation patterns discovered in SHANK3 gene in cerebella tissue of ASD patients |
| [115]   | ATP    | Brain tissue | 20 subjects | Epigenetic study | Enrichment of 5-hmc in cerebella tissue may be associated with increased binding by MECP2 to RELN and GAD1 promoters |

Study numbers listed as families or subjects wherever applicable
pathways and drug targets of such a multi-factorial disease of ASD which involves hundreds of risk factors.

Stem cell research and autism spectrum stem cell resource

A major impediment to recent drug discovery particularly in the field of neuroscience is the lack of human cell models. The iPSC technology developed by Nobel Laureate Shinya Yamanaka has provided an excellent opportunity [126]. Fibroblasts from patients’ biopsy can be converted into iPSCs with defined transcription factors, which resemble embryonic stem cells and can become most cell types in our body. Therefore, patient-derived iPSCs may be used to investigate disease pathology, progression and mechanisms to create human disease models for drug screening and testing [127, 128].

The SSC has also commenced efforts to create iPSC lines from idiopathic ASD patients who have large head circumference but unknown gene association [129]. The iPSCs were grown into organoids to mimic cortical development, and ASD organoids were shown to display a disproportionate ratio of inhibitory: excitatory neurons. The cortical gene FOXG1 was overexpressed in ASD organoids, and this overexpression correlated with the severity of ASD and their head size [129]. This study has demonstrated a proof-of-concept to model ASD in culture stem cells.

The Children’s Hospital in Orange County California has set up a bio-collection dedicated to this task, the ASD Stem Cell Resource. ASD patients were screened and accepted based on the following criteria: ASD patients if they have no other conditions (i.e. trauma, stroke, seizure disorders) affecting the central nervous system other than ASD; if they have no features of other known genetic conditions (e.g. tuberous sclerosis); Fragile X patients if they are genotypically confirmed for FMR1 the CGG repeat number of the FMR1 gene found to be associated with language impairment and dyslexia, respectively

As of 2014, this resource was composed of iPSCs from 200 unaffected donors and patients. The collection includes fibroblasts, blood, iPSCs, iPSC-derived neuronal and glial cells. The first study published using this bio-collection was the iPSC models of Fragile X syndrome [130]. The Fragile X patient fibroblasts were used to derive iPSCs and differentiate into neurons for transcriptomic analysis. The neuronal differentiation genes (WNT1, BMP4, POU3F4, TFAP2C, PAX3) were shown to be up-regulated, whereas potassium channel genes (KCNA1, KCNC3, KCNG2, KCNIP4, KCNJ3, KCNK9, KCNT1) were downregulated in Fragile X iPSC-derived neurons. The temporal regulation of SHANK1 and NNAT genes were also altered, with reduced SHANK1 mRNA and increased NNAT mRNA in patient cells. While the stem cell collection is relatively new, it has great potential to facilitate brain cell culture in vitro, which would otherwise not be feasible by using post mortem brain tissue.

| Reference | Biobank | Sample type | Number | Study | Findings |
|-----------|---------|-------------|--------|-------|----------|
| [119] | SSC and AGRE | Blood and genomic data | 8044 subjects (AGRE) 4348 subjects (SSC) | Genome-wide survey on translational effects | Investigation of maternal genetic effects in ASD. Validation using other data sets (SSC and AGRE did not reproduce similar results). |
| [354] | SSC and AGRE | Genomic and clinical data | Subjects (AGRE) 941 1048 subjects (SSC) | Gene association study | ATP2C2 and MRPL19 found to be associated with language impairment and dyslexia, respectively |
| [122] | SSC and AGRE | Blood | AGRE–127 subjects SSC–75 subjects | Parallel sequencing study | Rare variants of the AFF2 gene found to be associated with ASD susceptibility in males |
| [355] | SSC and AGRE | Genomic data | 359 subjects (AGRE) 55–885 subjects | GWAS | Female protective effect in ASD is not mediated by a single genetic locus. |
| [356] | AGRE and SSC | Genomic data | 13 subjects (AGRE) 3 subjects (SSC) | WES | Loss of CTNND2 function linked to severe ASD |
| [86] | SSC and TASC | Blood and lymphoblasts | 15480 (total) 2475(SSC) 601(TASC) | WES | 107 genes implicated in ASD. These genes are responsible for synaptic formation, chromatin remodelling and transcriptional regulation |
| [123] | SSC and AGRE | Blood and lymphoblasts, genomic and clinical data | 5657 subjects (total) 1555 subjects (AGRE) 872 subjects (SSC) | WES | Mutations in SHANK1, 2 and 3 accounts for 1 in 50 ASD cases. SHANK1 mutations linked to mild effects, SHANK2 for moderate and SHANK2 for severe. |

Study numbers listed as families or subjects wherever applicable
Discussion
It is clear from the studies reviewed here that large ASD bio-collections have had an undiscputable impact on progressing genomic discovery in ASD, leading to enhanced understanding of ASD neurobiology. While many studies used private collections as sources for tissue and data, large and well characterised samples from the collections reviewed have supported the discovery of small genetic effects, e.g. in GWAS and rare genetic mutations such as pathogenic CNV and SNV but it is clear, as highlighted for other neurodevelopmental disorders such as Schizophrenia that larger samples are required. Both genetic and phenotypic heterogeneity are impediments to gene discovery. Large bio-collections aim to reduce these effects but challenges remain. Each of the bio-collections reviewed has its own strengths and limitations.

Phenotypic and genotypic heterogeneity
Some of the bio-collections, e.g. SSC, AGRE, TASC, reduced phenotypic heterogeneity through the use of research gold standards for ASD diagnosis, ADI-R andADOS. Different versions of these instruments based on the timeline when these data have been collected have been used. IQ measurement is more complex to calculate due to the broad range of IQ commonly included within bio-collections. Differences also exist in the clinical profile of subjects included in the different collections with some samples, e.g. SSC, comprised of more individuals with higher cognitive functioning relative to AGRE, TASC or AIC. Medical and psychiatric comorbidities [7] have greater recognition but are not as systematically evaluated in each of the collections. Differences in ascertainment are also relevant. The SSC focused on simplex autism, i.e. families where only one child was affected to maximise the detection of rare variants. Consequently, the relative contribution of common genetic risk within the SSC sample appears reduced. In contrast to autism specific bio-collections, the DNSB, provides a large population-based sample with clinical diagnosis that can maximise power within GWAS studies to detect common genetic variation but does not provide in-depth clinical data for phenotype-genotype analyses. This was evident in the studies on amniotic fluid and DBSS where different diagnostic criteria would have been applied at the time of the subjects’ diagnoses, meaning one criteria would have excluded subjects (ICD8) whereas another would not (ICD10) [95, 96] [93, 94].

Throughout the studies listed here, there is an imbalance of ethnicities of bio-collections, as many of the studies rely heavily on Caucasian/European descent, which has been pointed out in some journals [131] and should consider diverse family structures [132], which can otherwise lead to population stratification [133]. Fortunately, efforts are underway to explore genetics of ASD in other countries such as China [134] and Brazil [135], which will reinforce many of the earlier findings covered in this review.

Samples
Large collections providing DNA for genomics studies have been advantageous; however, as studies move beyond the scope of genetics into transcriptomics, epigenomics and proteomics, a wider variety of sample types will be required. Serum will be valuable for investigating circulating metabolites and proteins that are expressed peripherally, including chemokines [93, 95], cytokines [94, 96], neurotropins [136], MMPs [137] and hormones [138]; however, this may not be the most appropriate tissue to investigate brain relevant ASD genes and proteins. DBSS, which can be useful for WES [139, 140], methylation [141] and gene expression [142], would not be as useful as fresh drawn blood for WGS, as DBSS-derived DNA would need to be amplified prior to use for analysis, potentially causing bias.

However, human brain tissue is a rare resource; brain tissue is very difficult to access due to its scarcity, and the preservation methods used may limit studies being carried out. Also, the types of brain cells are dependent on brain tissue being used; neuronal tissue in grey matter or glial tissue in white matter. Many of the studies listed in the Autism BrainNet, for example, utilised certain sections of the brain; and the most commonly used sections are the prefrontal cortex, temporal cortex, Brodmann’s area, cerebellum and cingulate gyrus. While findings from these sections have been of crucial importance, a capacity to model the entire brain and to observe progression of ASD development would be ideal, and patient’s somatic cells can now be converted to iPSCs and then into disease cell types.

IPSCs have been used as disease models for Fragile X syndrome [143–145] and Rett syndrome [146], and iPSCs have been generated from patents with deletions in SHANK3 [147] which are implicated in a number of neurodevelopmental disorders. The three-dimensional culture is developed and iPSCs can also be used to create mini-organoids, which can come very close to mimicking aspects of brain development [129, 148]. In addition to the brain cell types discussed earlier [129, 149], the iPSCs could be used to generate other cell types implicated in ASD co-morbidities, such as the gut [88, 150] and the blood brain barrier [151, 152].

Fibroblasts are the first cell type used to make iPSCs from mice [126] and humans [153] and remain as the most popular cell type for generating neural stem cells, neurons or iPSCs. Fibroblasts are easier to reprogram than many other somatic cells, and the reprogramming efficiency is between 0.1–1% depending on the reprogramming method [154]. They require basic culture
media and proliferate rapidly, so large numbers of fibroblasts can be generated in a short period. Unlike keratinocytes they require trained medical personnel to obtain skin biopsies, which could be distressing to some ASD patients. Low passages of fibroblasts are required for reprogramming as higher passages dramatically reduce reprogramming efficiency and increase genomic instability [155]. In addition to their use for iPSCs, fibroblasts can be used to investigate amino acid transport, and ASD fibroblasts were found to have greater affinity for transporting alanine, but less affinity for tyrosine—a key component for the synthesis of the neurotransmitter dopamine [156]. Fibroblasts can be used as a proxy to investigate transport across the blood-brain barrier [156, 157] and to investigate calcium signalling [158, 159].

Keratinocytes can also be used for generating iPSCs [160]. Collection is less invasive than skin biopsy and can be carried out by non-medical personnel. The hair samples are easy to transport and culture and transformed cells are easier to identify and isolate. Similar to fibroblasts, keratinocytes are reprogrammed at low passages and fewer methods have been employed to reprogram keratinocytes than fibroblasts. The lentiviral, retroviral and episomal reprogramming were tried successfully [155, 161, 162], and keratinocytes were shown to have high reprogramming efficiency of 1–2%. The major challenge is the reproducibility of keratinocyte growth, and it often requires repeated rounds of hair plucking from a same donor.

Organization
There are many generic articles and white papers for biobanks available, including consensus best-practice recommendations. For those who may wish to start their own bio-collections, we have listed a few articles in Table 7 for further reading on topics pertaining to collection, management, sustainability and quality control. In addition, links to international guidelines can be found here (http://www.oecd.org/sti/biotech/guidelinesforhumanbiobanksandgeneticresearchdatabaseshbgdhrs.htm; http://www.isber.org/?page=BPR; https://biospecimens.cancer.gov/practices/). However, even when using best practice guidelines, the storage and use of bio samples will be subject to the laws where the facilities are located, and will vary from country to country [163].

Participation and ethics
Stakeholders can have a considerable influence on how a bio-collection operates and how a bio-collection can be set up, managed and monitored [164]. In addition to researchers, clinicians and parents in bio-collections of ASD research, autistic stakeholders should be included as part of the stakeholder group, which could help guide and inform how research is carried out. A recent survey [165] was carried out amongst researcher-community engagement on ASD research in the UK. A high dissatisfaction and level of disengagement was expressed by parents and patients, who felt that research outcomes made little or no difference to their day-to-day lives and that they were not communicated, not involved or valued. Patients also felt that they did not receive follow-up and researchers were unapproachable and driven by data collection. Establishment and sustainability of a good stakeholder engagement are essential in ASD research and in biobanking. This will not only help guide research to subjects that matter to the community, but also the future of the biobank. One initiative, such as SPARK (Simons Foundation Powering Autism Research for Knowledge) is underway to encourage ASD communities in the USA to participate in ASD research. While such a goal is laudable, it is crucial that participants are engaged in the entire process. They are not just the suppliers of biocollections for research and data collection, but also make an input into research areas, which directly impinge on the quality of their life. Meanwhile, regular public events to update research progress and challenges to the stakeholder community may help win their understanding, appreciation and continuous support.

The ethics and obtainment of consent are significant factors for bio-collection research. The main considerations include what information shall be given to potential donors regarding the protocol and its implications of the research, how consent should be obtained [166] or what shall be done if consent was not clearly given [167]. It is also a matter of debate whether the consent should be “broad” and if the patient shall consent to a framework of research; if ethical review of each project shall be carried out by independent committees, and what are the strategies to inform and renew consent if

| Table 7 Description of papers relating to aspects of biobanking |
|---------------------------------------------------------------|
| Reference | Subject of paper |
|----------|------------------|
| [357]    | Introduces concept of adding value to stakeholders (patient donors/funders/research customers) and to find balance between aspects of sustainability (acceptability/efficiency/ accomplishment) |
| [358]    | Feasibility of simplified consent form for biobanking. Result indicates simplified forms combined with supplemental information for further reading effective in minimising form length and complexity |
| [359]    | Review paper detailing best practice guidelines for sample collection and storage, management of data and infrastructure. In addition, ethical, legal and social issues are explored |
| [360]    | Paper discussing aspects of embryonic stem cell banking that can be applied to iPSCS |
| [361]    | Key issues relating to delivery and safety testing of iPSC stocks for use in research and therapy. Importance of international and national coordinated banking systems are also discussed |
| [362]    | Description of enclosed culture system for iPSCS and neural precursors for use in preclinical and basic research |
there is significant deviation of framework; where shall the consent be revisited and renewed for every new study [168]; how the data will be protected and accessed [169, 170]; and how the findings will be communicated [171]. The latter is especially important if findings are of clinical significance to certain donors or it may affect their health or well-being [167]. These are the issues that each ethical application faces in making the application.

For people with ASD, it can be very complicated. Parents will give consent for their children if they want to donate samples for the bio-collection, but there is a question of adults who may not have the ability to give consent or to fully understand the implications. It is also important to clearly communicate what this research will mean for the patient and the family, including findings that may be of pathological as well as clinical significance. Liu and Scott have commented on how the discoveries made in ASD research can be distorted by media. If parents/patients are misled to believe that a cure will come out a few years down the road, this may lead to disappointment and make them reluctant to participate in further research. Liu and Scott pointed out that the Neurodiversity Movement group (high-functioning autistics) would have issues with certain research. They will not participate in research if they feel it may threaten or undermine people with ASD [128]. They prefer investment on services and therapies, rather than on genetic studies which may result in prevention of autistics being born [172–174], and the idea of curing autism is a complicated topic of debate [175].

For iPSC research, it was suggested to educate participants on the current state of research, to clearly explain the benefits and risks of biopsy donation and to consult the ASD community on research focus of an ASD bio-collection and on distribution of the cell lines [128]. For clinical trials of stem cells, stem cell counsellors shall inform participants the benefits and risks of enrolling in stem cell trials and to safeguard them from the dangers of stem cell tourism. Such an approach should also be considered for ASD-related studies [176].

Conclusions
In conclusion, bio-collections have been shown as valuable resources and enabled large-scale studies on ASD. The recent genetic studies have begun to reveal de novo mutations on major cellular pathways [17, 177]. There is also emerging evidence that ASD continuum contains subgroups with discrete mutations in specific genes such as CDH8 [88], DYSK1A [71] and POGZ [90] and gene mutations like NRXN1 [28, 60, 73, 178, 179] and SHANKs [72, 98, 114, 123] recurring in broad populations. There is a vast amount of clinical and biological information available in these bio-collections, and the data are in the need for concrete guidelines on ethics and governance. The communication and trust shall be maintained between the researchers and families who have given biological and personal information. Finally, the availability of iPSC resources dedicated to idiopathic and syndromic forms of ASD could be a tremendous boon to the research community and such models are anticipated to be complementary with animal models and to speed up the development of therapeutic interventions for ASD. They could open up the possibilities of functional studies of ASD on a large scale and could become a future model for other iPSC bio-collections to be set up worldwide.

Abbreviations
AD: Autism Diagnostic Interview–Revised; ADOS: Autistic Diagnostic Observation Schedule; AGP: Autism Genome Project; AGRE: Autism Genetic Resource Exchange; AIC: Autism Inpatient Collection; ASD: Autism spectrum disorders; ATP: Autism tissue program; CAN: Cure Autism Now Foundation; CCGSMID: Centre for Collaborative Genetic Studies on Mental Disorders; CNV: Copy number variation; DBC: Danish Birth Cohort; DBSS: Dried blood spot samples; DNSB: Danish Newborn Screening Biobank; DSM-5: Diagnostic and Statistical Manual of Mental Disorders; GSH: Glutathione; GWAS: Genome-wide association study; HAWAS: Histone acetylome-wide association study; HD: Human Biological Data Interchange; ICD: International Statistical Classification of Diseases and Related Health Problems; iPSC: Induced pluripotent stem cells; MMP: Matrix metalloproteinase; MPLA: Multiplex ligation-dependent probe amplification; PDD-NOS: Pervasive developmental disorder not otherwise specified; RUCDR: Rutgers University Cell and DNA Repository; SCD: Social (pragmatic) communication disorder; SNP: Single nucleotide polymorphism; SNV: Single nucleotide variation; SSC: Simons Simplex Collection; TASC: Autism Simplex Collection; WES: Whole exome sequencing study

Acknowledgements
I would like to thank all authors who contributed to this manuscript

Funding
Not applicable.

Availability of data and materials
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors’ contributions
JR collected the literature and wrote the manuscript and tables. JLC authored the search criteria section. SS, LG and GL gave feedback and suggested changes which were incorporated into the manuscript. All authors read and approved the final manuscript.

Authors’ information
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Regenerative Medicine Institute, School of Medicine, BioMedical Sciences Building, National University of Ireland (NUI), Galway, Ireland. 2Trinity Translational Medicine Institute and Department of Psychiatry, Trinity Centre for Health Sciences, St. James Hospital Street, Dublin 8, Ireland. 3Department of Special Education, Faculty of Education, East China Normal University, Shanghai 200062, China. 4Irish Centre for Autism and Neurodevelopmental Research (ICAN), Department of Psychology, National University of Ireland Galway, University Road, Galway, Ireland.

Received: 16 March 2017 Accepted: 23 June 2017
Published online: 10 July 2017

References
1. Christensen DL, Bao J, Van Naarden Braun K, Bilder D, Charles I, Constantino JN, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ. 2016;65(1–23. doi:10.15585/mmwr.s6503a1.
2. Charman T. The prevalence of autism spectrum disorders. Recent evidence and future challenges. Eur Child Adolesc Psychiatry. 2002;11:249–56. doi:10.1007/s00787-002-0297-8.
3. Newschaffer CJ, Croen LA, Daniels J, Garrel E, Grether JK, LevS SE, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health. 2007;28:35–58. doi:10.1146/annurev.publhealth.28.021406.144007.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association, 2013.
5. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47:921–9.
6. Mazzone L, Ruta L, Reale L. Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges. Ann Gen Psychiatry.
7. Chen M-H, Su T-P, Chen Y-S, Hsu J-W, Huang K-L, Chang W-H, et al. Identification of significant association and gene-gene interaction of GABA protein 2 (MECP2) and affects the behavior of mice. J Biol Chem. 2011;286:585:585–62. doi:10.1074/jbc.M111.300541.
8. Rossignal DA, Feye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17:290–314. doi:10.1038/mp.2010.136.
9. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2012;26:383–92. doi:10.1016/j.bbi.2011.08.007.
10. Schanen NC, Epigenetics of autism spectrum disorders. Hum Mol Genet. 2006;15 Spec No 2:R138–50. doi:10.1093/hmg/ddl213.
11. Bourgeron T. From the genetic architecture to synaptic plasticity in autism. Neuron. 2015;80:551–562. doi:10.1016/j.neuron.2014.03.025.
12. Loat CS, Curran S, Lewis CM, Duval J, Geschwind D, Bolton P, et al. Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism. Genes Brain Behav. 2008;7:574–60. doi:10.1111/j.1601-183X.2008.00414.x.
order by microRNA expression profiling of lymphoblastoid cell lines. Genome Biol. 2010;2:23. doi:10.1186/gb-144.

80. Oguro-Ando A, Rosensweig C, Herman E, Nishimura Y, Welting D, Bill BR, et al. Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR. Mol Psychiatry. 2015;20:1069–78. doi:10.1038/mp.2014.124.

81. Faham M, Zheng J, Moorhead M, Fahkrai-Rad H, Namsaraev E, Wong K, et al. Multiplexed variation scanning for 1,000 amplicons in hundreds of patients using mismatch repair detection (MRD) on tag arrays. Proc Natl Acad Sci U S A. 2005;102:14717–22. doi:10.1073/pnas.0506677102.

82. Cai G, Edelmann L, Goldsmith JE, Cohen N, Nakamine A, Reichert JG, et al. Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics. 2008;1:50. doi:10.1186/1755-8794-1-50.

83. Bureau A, Labbe A, Croteau J, Mérette C. Using disease symptoms to improve detection of linkage under genetic heterogeneity. Genet Epidemiol. 2008;32:476–86. doi:10.1002/gepi.20202.

84. Yoon AJ, Palmer AA, Smith KC, Feldman I, Lee HK, Yoon JM, et al. Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction. Genes Brain Behav. 2003;2:203–20.

85. Turner TN, Hormozdiari F, Duyzend MH, McClymont SA, Hook PW, Iossifov I, et al. Genome Sequencing of Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA. Am J Hum Genet. 2016;9858–74. doi:10.1016/j.ajhg.2015.11.023.

86. De Rubertis S, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Dynamic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–14. doi:10.1038/nature13772.

87. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway B, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012;338:1619–23. doi:10.1126/science.1237764.

88. Berner R, Golozio C, Xiong B, Stessman HA, Cao BP, Penn O, et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell. 2014;158:263–76. doi:10.1016/j.cell.2014.06.017.

89. Conjetty J, Muhle RA, Sanders SJ, Liu L, Willeys AJ, Niu W, et al. The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. Nat Commun. 2015;6:6404. doi:10.1038/ncomms7404.

90. Steiner HAF, Willemsen MH, Fenchoua M, Penn O, Hoischen A, Xiong B, et al. Disruption of POQZ Is Associated with Intellectual Disability and Autism Spectrum Disorders. Am J Hum Genet. 2016;98:541–52. doi:10.1016/j.ajhg.2016.02.004.

91. Nørgaard-Pedersen B, Hougaard DM, et al. Neonatal chemokine levels and risk of autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics. 2008;1:50. doi:10.1186/1755-8794-1-50.

92. The Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium. Meta-analysis of GWAS of over 16,000 individuals identifies new risk variants that converge in pathways that associate with autism spectrum disorders. Nature. 2016;531:252–7. doi:10.1038/nature16926.

93. Abdallah MW, Larsen N, Grove J, Nørgaard-Pedersen B, Hougaard DM, et al. Neonatal chemokine levels and risk of autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics. 2008;1:50. doi:10.1186/1755-8794-1-50.

94. Bonefeld-Jørgensen EC, et al. Neonatal levels of cytokines and risk of autism spectrum disorders. Cytokine. 2013;61:370–9. doi:10.1016/j.cyto.2012.11.015.

95. Abdallah MW, Larsen N, Mortensen EL, Atladóttir HÓ, Nørgaard-Pedersen B, Bonefeld-Jørgensen EC, Nørgaard-Pedersen B, Hougaard DM, et al. Neonatal chemokine levels and risk of autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics. 2008;1:50. doi:10.1186/1755-8794-1-50.

96. Reilly et al. Molecular Autism (2017) 8:34 Page 29 of 36
119. Tsang KM, Croen LA, Torres AR, Kharazi M, Delorenze GN, Windham GC, et al. A genome-wide survey of transgenerational genetic effects in autism. PLoS ONE. 2013;8:e76978. doi:10.1371/journal.pone.0076978.

120. Desachy A, Croen LA, Torres AR, Kharazi M, Delorenze GN, Windham GC, et al. Increased female autosomal burden of rare copy number variants in human populations and in autism families. Mol Psychiatry. 2015;20:170–5. doi:10.1038/mp.2014.179.

121. Jacquemont S, Coe BP, Hersch M, Duyzend MH, Krumm N, Bergmann S, et al. A higher mutational burden in females supports a “female protective model” in neurodevelopmental disorders. Am J Hum Genet. 2014;94:415–25. doi:10.1016/j.ajhg.2014.02.001.

122. Mondal K, Ramachandran D, Patel VC, Hagen KR, Bose P, Cutler DJ, et al. Excess variants in AF22 detected by massively parallel sequencing of males with autism spectrum disorder. Hum Mol Genet. 2012;21:4356–64. doi:10.1093/hmg/dds267.

123. Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, Lumbroso S, et al. Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014;10:e1004580. doi:10.1371/journal.pgen.1004580.

124. Yuen RKC, Merico D, Hauw JJ, Pellecchia G, Alipanahi B, Thiruvahindrapuram B, et al. Genome-wide characteristics of de novo mutations in autism. npj Genomic Med. 2016;1:160271–160271. doi:10.1038/npjgenmed.2016.27.

125. C Yuen R, Merico D, Bookman M, L Howe J, Thiruvahindrapuram B, Patel RV, et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat Neurosci. 2017;20:602–6. doi:10.1038/nn.4524.

126. Takashiki K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126: 663–76. doi:10.1016/j.cell.2006.07.024.

127. Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPS-cell technologies. Stem Cell Rev. 2014;10:145–66. doi:10.1007/s12015-014-9497-0.

128. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasoni L, et al. FOXI1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell. 2015;162:375–90. doi:10.1016/j.cell.2015.06.034.

129. Lu P, Chen X, Feng Y, Zeng Q, Jiang C, Zhu X, et al. Integrated transcriptome analysis of human iPS cells derived from a fragile X syndrome patient during neuronal differentiation. Sci China Life Sci. 2016;59:1093–105. doi:10.1007/s11427-016-0194-6.

130. Pierce NP, O'Reilly MW, Sorells AM, Fragale CL, White PJ, Aguilar JM, et al. Ethnicity reporting practices for empirical research in three autism-related journals. J Autism Dev Disord. 2014;44:1507–19. doi:10.1007/s10803-014-1941-x.

131. Hilton CL, Fitzgerald RT, Jackson KM, Maxim RA, Bosworth CC, Shattuck PT, et al. Brief report: Under-representation of African americans in autism genetic–risk of autism spectrum disorders. Acta Psychiatr Scand. 2013;128:61–8. doi:10.1111/j.1600-0447.2012.01742.x.

132. Robinson EB, Howrigan D, Yang J, Ripke S, Anttila V, Duncan LE, et al. Response to “Predicting the diagnosis of autism spectrum disorder using gene pathway analysis”. Mol Psychiatry. 2014;19:589–61. doi:10.1038/mp.2013.125.

133. Wang T, Guo H, Xiong B, Stessman HAF, Wu H, Coe BP, et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. Nat Commun. 2016;7:13316. doi:10.1038/ncomms13316.

134. Nascimento PP, Bossolani-Martins AL, Rosan DBA, Mattos LC, Brandão-Mattoz C, Fett-Conte AC. Single nucleotide polymorphisms in the CNTNAP2 gene in Brazilian patients with autistic spectrum disorder. Genet Mol Res. 2016;15:10.4238/gmr.15017422.

135. Abdallah MW, Mortensen EL, Greaves-Lord K, Larsen N, Bonefeld-Jorgensen EC, Nørgaard-Pedersen B, et al. Neonatal levels of neurotrophic factors and risk of autism spectrum disorders. Acta Psychiatr Scand. 2013;128:61–9. doi:10.1111/acps.12020.

136. Abdallah MW, Pearce BD, Larsen N, Greaves-Lord K, Nørgaard-Pedersen B, Hougaard DM, et al. Amnionic fluid MMP-9 and neurotrophins in autism spectrum disorders: an exploratory study. Autism Res. 2015;25:428–33. doi:10.1002/aur.1254.

137. Baron-Cohen S, Auyeung B, Nørgaard-Pedersen B, Hougaard DM, Abdallah MW, Melgaard L, et al. Elevated fetal steroidogenic activity in autism. Mol Psychiatry. 2015;20:369–76. doi:10.1038/mp.2014.48.
161. Streekstra-Bômeke K, Wolf F, Azizian A, Stauske M, Tiburcy M, Wagner S, et al. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J. 2013;34:2616–29. doi:10.1093/eurheartj/ehs203.

162. Piao Y, Hung SS-C, Lim SY, Wong RC-B, Ko MSH. Efficient generation of integration-free human induced pluripotent stem cells from keratinocytes by simple transfection of epicorical vectors. Stem Cells Transl Med. 2014;3:787–91. doi:10.5966/sctm.2013-0036.

163. Chalmers D, Nicol D, Kaye J, Bell J, Campbell AV, Ho CWL, et al. Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era. BMC Med Ethics. 2016;17:39. doi:10.1186/s12910-016-0134-2.

164. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, Kamdar S, et al. Molecular cytogenetic analysis and sequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet. 2008;82:165–73. doi:10.1016/j.ajhg.2007.09.017.

165. Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, Hollander E, et al. Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet. 2001;68:S154–6. doi:10.1086/320588.

166. Anitha A, Thanseem I, Nakamura K, Yamada K, Iwayama Y, Toyota T, et al. Protocadherin 9a (PCDH9A) as a novel susceptibility gene for autism. J Psychiatry Neurosci. 2013;38:192–8. doi:10.1503/jpn.120508.

167. Bakkaloglu B, O’Roak BJ, Louvi A, Gupta AR, Abelson JF, Morgan TM, et al. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J. 2013;34:2616–29. doi:10.1093/eurheartj/ehs203.
autism candidate region at 7q31. Genomics. 2001;78:7–11. doi:10.1006/geno.2001.6651.

204. Concatorri M, Stodgel CJ, Hyman SL, O'Bara M, Miliomeni R, Bravaccio C, et al. Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism. Biol Psychiatry. 2004;55:413–9. doi:10.1016/j.biopsych.2003.10.005.

205. Connolly JJ, Glessner JT, Hakonarson H. A genome-wide association study of autism incorporating autism diagnostic interview-revised, autism diagnostic observation schedule, and social responsiveness scale. Child Dev. 2013;84:17–33. doi:10.1111/cd.2012.01838.x.

206. Connors SL, Crowell DE, Eberhart CG, Copeland J, Newschaffer CJ, Spence DE, et al. A Quantitative Trait Locus Analysis of Social Responsiveness in Autism: data from dizygotic twins. J Child Neurol. 2005;20:876–84. doi:10.1177/088303700502101401.

207. D'Amaro E, Ricci I, Sacco R, Liu X, D'Agruma L, Muscarella LA, et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry. 2005;10:1006–16. doi:10.1038/mp.2005.21.

208. Davis LA, Meyer KJ, Rudder DS, Libran AL, Epping EA, Sheffield VC, et al. Novel copy number variants in children with autism and additional developmental anomalies. J Neurodev Disord. 2009;1:292–301. doi:10.1007/s11689-009-9013-z.

209. Dennis MY, Nuttle X, Sudmant PH, Antonacci F, Graves TA, Nefedov M, et al. Evolution of human-specific neural SRGAP2 genes by incomplete segmental duplication. Cell. 2012;149:912–22. doi:10.1016/j.cell.2012.03.033.

210. Davalli J, A Quantitative Trait Locus Analysis of Social Responsiveness in Multiplex Autism Families. Am J Psychiatry. 2007;164:656s. doi:10.1546/ajp.2007.656s.

211. Yonen AI, Alarcón M, Cheng R, Magnusson PK, Spence SJ, Palmer AA, et al. A Genomewide Screen of 345 Families for Autism-Susceptibility Loci. Am J Hum Genet. 2003;73:388–97. doi:10.1086/378778.

212. Fatemi SH, Stacy JM, Egan EA. Reduced blood levels of reelin as a vulnerability factor in pathophysiology of autistic disease. Cell Mol Neurobiol. 2002;22:139–52.

213. Cistemas FA, Vincent JB, Scherer SW, Ray PN. Cloning and characterization of human CADPS and CADPS2, new members of the Caa2++-dependent activator for secretion protein family. Genomics. 2003;81:279–91. doi:10.1016/S0888-7543(02)00040-X.

214. Flax JF, Hare A, Azaro MA, Veland VJ, Brazustowicz LM. Combined linkage and linkage disequilibrium analysis of a motor speech phenotype within autism spectrum disorders. J Dev Behav Pediatr. 2011;32:254–60. doi:10.1097/DBP.0b013e31821155f9.

215. Fradin D, Cheslack-Postava K, Ladd-Acosta C, Newschaffer C, Chakravarti A, Flax JF, Hare A, Azaro MA, Vieland VJ, Brzustowicz LM. Combined linkage disequilibrium analysis of a motor speech phenotype within autism spectrum disorders. J Dev Behav Pediatr. 2011;32:254–60. doi:10.1097/DBP.0b013e31821155f9.

216. Kistner-Griffin E, Brune CW, Davis LK, Sutcliffe JS, Cox NJ, Cook EH. Parent-of-origin effects of the serotonin transporter gene associated with autism. Am J Med Genet B Neuropsychiatr Genet. 2011;156:139–44. doi:10.1002/ajmg.b.31146.

217. Kumar RA, Sudi J, Babatz TD, Brune CW, Oswald D, Yen M, et al. A de novo 1p34.2 microdeletion identifies the synaptic vesicle gene RIMS3 as a novel candidate for autism. J Med Genet. 2010;47:81–90. doi:10.1136/jmg.2008.055821.

218. Lee LC, Zachary AA, Leffell MS, Newschaffer CJ, Matteson KJ, Tyler JD, et al. HLA-DRA4 in families with autism. Pediatr Neurol. 2006;35:303–7. doi:10.1016/j.pediatrneurol.2006.06.006.

219. Liu X, Malefanft P, Reesor C, Lee A, Hudson ML, Harvard C, et al. 2p15-16.1 microdeletion syndrome: molecular characterization and association of the OTX1 and KPO1 genes with autism spectrum disorders. Eur J Hum Genet. 2011;19:1264–70. doi:10.1038/ejhg.2011.112.

220. Liu X, Novosedlik N, Wang A, Hudson ML, Cohen IL, Chudley AE, et al. The DLX1and DLX2 genes and susceptibility to autism spectrum disorders. Eur J Hum Genet. 2009;17:228–35. doi:10.1038/ejhg.2008.148.

221. Liu X, Solehedin F, Cohen IL, Gonzalez MG, Jenkins EC, Lewis MES, et al. Population- and family-based studies associate the MTHFR gene with idiopathic autism in simple autistic families. J Autism Dev Disord. 2011;41:938–44. doi:10.1007/s10803-010-1120-x.

222. Lu ATH, Cantor RM. Allowing for sex differences increases power in a GWAS of multiplex autism families. Mol Psychiatry. 2012;17:215–22. doi:10.1038/mp.2012.127.

223. Lu AT-H, Dai X, Martinez-Agosto JA, Cantor RM. Support for calcium channel gene defects in autism spectrum disorders. Mol Autism. 2012;3:18. doi:10.1186/2040-2392-3-18.

224. Ma D, Saliyana DJ, Jaworski JM, Konidari I, Whitehead PL, Andersen AN, et al. A genome-wide association study of autism reveals a common novel risk locus at 5p14.1. Ann Hum Genet. 2009;73(Pt 3):263–73. doi:10.1111/j.1469-1809.2009.00523.x.

225. Malenfant F, Liu X, Hudson ML, Qiao Y, Hrynczak M, Rendeau N, et al. Association of GTF2 in the Williams-Beuren syndrome critical region with autism spectrum disorders. J Autism Dev Disord. 2012;42:459–69. doi:10.1007/s10803-011-1389-4.

226. Martin CL, Duvall JA, Iliny I, Simon JS, Arreaza MG, Wilkes K, et al. Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:968–967. doi:10.1002/ajmg.b.30830.

227. Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amiral DG. Stereotyped and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22:806–16. doi:10.1016/j.bbi.2007.12.007.

228. Maisson G, Carayol V, Lepagnol-Bestel A-M, Tores F, Loe-Meyer Y, Milbreta U, et al. Convergent evidence identifying MAP/microtubule affinity-regulating kinase 1 (MARK1) as a susceptibility gene for autism. Hum Mol Genet. 2008;17:2541–51. doi:10.1093/hmg/ddt136.

229. McCauley JL, Li C, Jiang L, Olson LM, Crockett G, Gainer K, et al. Genome-wide and Ordered-Subset linkage analyses provide support for autism loci on 17q and 19p with evidence of phenotypic and interlocus genetic correlations. BMC Med Genet. 2005;6:s1. doi:10.1186/1471-2350-6-1.

230. McNamara LA, Nakamine A, Pilorge M, Brandt T, Jimenez Gonzalez P, Fallas M, et al. A large-scale survey of the novel 15q24 microdeletion syndrome in autism spectrum disorders identifies an atypical deletion that narrows the critical region. Mol Autism. 2010;1:5. doi:10.1186/2040-2392-1-5.

231. Meyer WK, Arbeithuber B, Ober C, Ebner T, Tiemann-Boege I, Hudson RR, et al. Evaluating the evidence for transmission distortion in human pedigrees. Genet Epidemiol. 2012;36:215–32. doi:10.1002/gepi.21357.
transporter KC22, in human autism and schizophrenia. Front Cell Neurosci. 2015;9:386. doi:10.3389/fncel.2015.00386.

321. Moreno-DeLuca D, SGENE Consortium, Muller JG, Simons Simplex Collection Genetics Consortium, Kaminsky EB, Sanders SJ, et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet. 2010;87:518–30. doi:10.1016/j.ajhg.2010.10.004.

322. Moreno-DeLuca D, Sanders SJ, Wilsey AJ, Muller JG, Lowe JK, Geschwind DH, et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol Psychiatry. 2013;18:1090–5. doi:10.1038/mp.2012.138.

323. Murdoch JD, Gupta AR, Sanders SJ, Walker MF, Keaney J, Fernandez TV, et al. No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins. PLoS Genet. 2015;11:e1004852. doi:10.1371/journal.pgen.1004852.

324. Noh HJ, Ponting CP, Boulding HC, Meader S, Betancur C, Buxbaum JD, et al. No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins. PLoS Genet. 2015;11:e1004852. doi:10.1371/journal.pgen.1004852.

325. Noh HJ, Ponting CP, Boulding HC, Meader S, Betancur C, Buxbaum JD, et al. No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins. PLoS Genet. 2015;11:e1004852. doi:10.1371/journal.pgen.1004852.

326. Peters SU, Hundley RJ, Wilson AK, Warren Z, Vehorn A, Carvalho CMB, et al. No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins. PLoS Genet. 2015;11:e1004852. doi:10.1371/journal.pgen.1004852.

327. Peters SU, Hundley RJ, Wilson AK, Warren Z, Vehorn A, Carvalho CMB, et al. No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins. PLoS Genet. 2015;11:e1004852. doi:10.1371/journal.pgen.1004852.

328. Robinson EB, St Pourcain B, Ansttila V, Kosmicki JA, Bulik-Sullivan B, Grove J, et al. Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population. Nat Genet. 2016;48:552–5. doi:10.1038/ng.3529.

329. Skafidas E, Testa R, Zantomio D, Chana G, Everall IP, Pantelis C. Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Mol Psychiatry. 2014;19:504–10. doi:10.1038/mp.2012.126.

330. Stanco A, Pla R, Vogt D, Chen Y, Mandal S, Walker J, et al. NPAS1 represses mitochondrial DNA heteroplasmy in autism spectrum disorder. PLoS Genet. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

331. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

332. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

333. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

334. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

335. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

336. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.

337. Thanseem I, Nakamura K, Anitha A, Suda S, Yamada K, Iwayama Y, et al. Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. Cell. 2016;12:e1006391. doi:10.1371/journal.pgen.1006391.
360. Stacey GN, Crook JM, Hei D, Ludwig T. Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells? Cell Stem Cell. 2013; 13:385–8. doi:10.1016/j.stem.2013.09.007.

361. Aoi T, Stacey G. Impact of National and International Stem Cell Banking Initiatives on progress in the field of cell therapy: IABS-JST Joint Workshop: Summary for Session S. Biologicals. 2015;43:399–401. doi:10.1016/j.biologicals.2015.07.007.

362. Stover AE, Herculian S, Banuelos MG, Navarro SL, Jenkins MP, Schwartz PH. Culturing human pluripotent and neural stem cells in an enclosed cell culture system for basic and preclinical research. J Vis Exp. 2016. doi:10.3791/53685.